10540336.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTADK01625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
NEWS  1          Web Page for STN Seminar Schedule - N. America
NEWS  2  MAR 15  WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS  3  MAR 16  CASREACT coverage extended
NEWS  4  MAR 20  MARPAT now updated daily
NEWS  5  MAR 22  LWPI reloaded
NEWS  6  MAR 30  RDISCLOSURE reloaded with enhancements
NEWS  7  APR 02  JICST-EPLUS removed from database clusters and STN
NEWS  8  APR 30  GENBANK reloaded and enhanced with Genome Project ID field
NEWS  9  APR 30  CHEMCATS enhanced with 1.2 million new records
NEWS 10  APR 30  CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 11  APR 30  INPADOC replaced by INPADOCDB on STN
NEWS 12  MAY 01  New CAS web site launched
NEWS 13  MAY 08  CA/CAplus Indian patent publication number format defined
NEWS 14  MAY 14  RDISCLOSURE on STN Easy enhanced with new search and display
                 fields
NEWS 15  MAY 21  BIOSIS reloaded and enhanced with archival data
NEWS 16  MAY 21  TOXCENTER enhanced with BIOSIS reload
NEWS 17  MAY 21  CA/CAplus enhanced with additional kind codes for German
                 patents
NEWS 18  MAY 22  CA/CAplus enhanced with IPC reclassification in Japanese
                 patents
NEWS 19  JUN 27  CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20  JUN 29  STN Viewer now available
NEWS 21  JUN 29  STN Express, Version 8.2, now available
NEWS 22  JUL 02  LEMBASE coverage updated
NEWS 23  JUL 02  LMEDLINE coverage updated
NEWS 24  JUL 02  SCISEARCH enhanced with complete author names
NEWS 25  JUL 02  CHEMCATS accession numbers revised
NEWS 26  JUL 02  CA/CAplus enhanced with utility model patents from China

NEWS EXPRESS  29 JUNE 2007:  CURRENT WINDOWS VERSION IS V8.2,
              CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
              AND CURRENT DISCOVER FILE IS DATED 4 MAY 2007.

NEWS HOURS    STN Operating Hours Plus Help Desk Availability
NEWS LOGIN    Welcome Banner and News Items
NEWS IPC8     For general information regarding STN implementation of IPC 8
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

10540336.trn

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:51:11 ON 03 JUL 2007

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

FILE 'REGISTRY' ENTERED AT 16:51:33 ON 03 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 JUL 2007 HIGHEST RN 940883-34-1
DICTIONARY FILE UPDATES: 2 JUL 2007 HIGHEST RN 940883-34-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10540336.str

10540336.trn



```
ring nodes :
1  2  3  4  5  6  7  8  9  10  17  18  19  20  21  22
ring/chain nodes :
11  12  13  14  15  16
ring/chain bonds :
7-17  10-11  11-12  13-15  13-14  15-16
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10  17-18  17-22  18-19  19-20
 20-21  21-22
exact/norm bonds :
5-7  6-10  7-8  7-17  8-9  9-10  10-11  11-12  13-15  13-14  15-16
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  17-18  17-22  18-19  19-20  20-21  21-22

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:Atom  18:Atom
19:Atom  20:Atom  21:Atom  22:Atom  23:Atom


L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```

10540336.trn



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 16:51:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    67212 TO ITERATE

  3.0% PROCESSED     2000 ITERATIONS                                  1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:      1328800 TO  1359680
PROJECTED ANSWERS:             325 TO     1019

L2             1 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10540336number2.str
```



```
ring nodes :
1  2  3  4  5  6  7  8  9  10  17  18  19  20  21  22
ring/chain nodes :
11  12  13  14  15  16
ring/chain bonds :
3-13  7-17  10-11  11-12  13-15  13-14  15-16
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10  17-18  17-22  18-19  19-20
 20-21  21-22
exact/norm bonds :
3-13  5-7  6-10  7-8  7-17  8-9  9-10  10-11  11-12  13-15  13-14  15-16
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  17-18  17-22  18-19  19-20  20-21  21-22

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:Atom  18:Atom
19:Atom  20:Atom  21:Atom  22:Atom


L3       STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3                STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l3
SAMPLE SEARCH INITIATED 16:53:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     40330 TO ITERATE

  5.0% PROCESSED      2000 ITERATIONS                                  1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:   ONLINE  **COMPLETE**
                         BATCH   **COMPLETE**
PROJECTED ITERATIONS:       794604 TO   818596
PROJECTED ANSWERS:             134 TO      672

L4             1 SEA SSS SAM L3

=> s l3 full
FULL SEARCH INITIATED 16:53:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    803184 TO ITERATE

100.0% PROCESSED    803184 ITERATIONS                                237 ANSWERS
SEARCH TIME: 00.00.03

L5           237 SEA SSS FUL L3

=> d scan
```
























L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-6-hydroxy-7-methoxy-6-(6-methoxyphenyl)-2,2,4-trimethyl-6-quinolinyl]-2,3,6-trimethyl-
MF C31 H34 N2 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, 2,2,2-trifluoro-N-[1,2,3,4-tetrahydro-2,2,4-trimethyl-3-(1-oxopentyl)-6-phenyl-6-quinolinyl]- (9CI)
MF C23 H29 F3 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl]-3-[2-ethoxyethoxy]- (9CI)
MF C27 H36 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanoic acid, 3-[[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-(6-methylphenyl)-6-quinolinyl]amino]-3-oxo-, ethyl ester (9CI)
MF C26 H32 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10540336.trn

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-2-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl]-6-methyl- (9CI)
MF C34 H34 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, 2,2,2-trifluoro-N-[1,2,3,4-tetrahydro-2,2,4-trimethyl-6-[6-(1-oxopentyl)-6-quinolinyl]- (9CI)
MF C25 H29 F3 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-[6-[3-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-3-[(trifluoromethyl)-, monomethanesulfonate (9CI)
MF C34 H38 F3 N3 O4 . C H4 O3 S
CM 1



CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-[6-[3-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-3,5-dichloro- (9CI)
MF C34 H36 Cl2 N2 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10540336.trn

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-6-[2-[2-hydroxy-1,1-dimethyl(ethyl)amino]ethoxy]phenyl]-1,2,4-trimethyl-6-quinolinyl]- (9CI)
MF C29 H45 N3 O4
CI HCl



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-[4-[3-[(3-pyridinylmethyl)amino]-1-propynyl]phenyl]-6-quinolinyl]-
MF C41 H40 N4 O4
CI COM



PAGE 1-A



PAGE 1-B

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-[4-[3-[(3-pyridinylmethyl)amino]-1-propynyl]phenyl]-6-quinolinyl]-, monomethanesulfonate (9CI)
MF C40 H43 N3 O3 . C2 H F3 O2
CM 1



CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-[(3-pyridinylmethyl)amino]-6-quinolinyl]-3,5-dibromo- (9CI)
MF C33 H32 Br2 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10540336.trn

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, (1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)-, 9H-fluoren-9-ylmethyl ester (9CI)
MF C35 H34 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-7-[3-aminopropyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-(6-quinolinyl]-3,5-dibromo- (9CI)
MF C29 H31 Br2 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-6-hydroxy-6-(6-hydroxyphenyl)-7-methoxy-2,2,4-trimethyl-6-quinolinyl]-3,5-dichloro- (9CI)
MF C26 H26 Cl2 N2 O4

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-6-[6-(1-methylphenoxy)-6-(1-oxobutyl)-6-quinolinyl]- (9CI)
MF C35 H39 F2 N2 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Pyrrolidinepropenamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-3-(4-phenyl-6-quinolinyl)-2-pro- (9CI)
MF C27 H28 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl)- (9CI)
MF C34 H34 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl)-3-(trifluoromethyl)- (9CI)
MF C30 H29 F3 N2 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-[4-[3-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl)-3-(trifluoromethyl)- (9CI)
MF C30 H32 F3 N3 O3
CI COM

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl)-3-(trifluoromethyl)- (9CI)
MF C30 H32 F3 N3 O3 . C2 H2 O4
CM 1



CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl)-, mono(trifluoroacetate) (9CI)
MF C32 H33 N3 O4 . C2 H F3 O2

CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-[4-[3-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl)-, mono(trifluoroacetate) (9CI)
MF C32 H33 N3 O4 . C2 H F3 O2

CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-[4-[3-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl)-, mono(trifluoroacetate) (9CI)
MF C32 H33 N3 O4 . C2 H F3 O2

CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-[2-[methyl(trimethylsilyl)amino]ethoxy]phenyl]-6-quinolinyl)- (9CI)
MF C34 H42 N2 O2 Si



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-[4-[2-(trimethylsilyl)ethoxy]phenyl]-6-quinolinyl)-, mono(trifluoroacetate) (9CI)
MF C34 H42 N2 O2 Si . C2 H F3 O2



CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3-Thiophenecarboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-7-[(phenylmethyl)amino]-6-quinolinyl]-5-methyl- (9CI)
MF C37 H33 N3 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Furancarboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-7-hydroxy-2,2,4-trimethyl-6-phenyl-6-quinolinyl]-5-[(dimethylamino)methyl]- (9CI)
MF C31 H33 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Propanamide, 3-(3-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)- (9CI)
MF C21 H24 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Furancarboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-[(4-phenyl-6-quinolinyl)amino]- (9CI)
MF C30 H29 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-7-hydroxy-2,2,4-trimethyl-6-phenyl-6-quinolinyl)-3,5-dimethoxy- (9CI)
MF C27 H28 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)-3-(phenylamino)- (9CI)
MF C31 H31 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Furancarboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-[(4-methylphenyl)-6-quinolinyl]- (9CI)
MF C30 H28 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-4-(3-pyridinyl)- (9CI)
MF C32 H31 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-7-[3-(1-piperidinyl)propoxy]-6-quinolinyl]- (9CI)
MF C41 H47 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-4-(dimethylamino)-, mono(trifluoroacetate) (9CI)
MF C35 H44 N4 O4 . C2 H F3 O2

CM 1



CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-3,5-dimethyl- (9CI)
MF C35 H43 N3 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-4-[4-(2-hydroxyethoxy)phenyl]-2,2,4-trimethyl-6-quinolinyl]- (9CI)
MF C35 H36 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-(diethylamino)-2-oxoethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]- (9CI)
MF C39 H43 N3 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-(2-pyridinylmethoxy)phenyl]-6-quinolinyl]-, mono(trifluoroacetate) (9CI)
MF C39 H37 N3 O3 . C2 H F3 O2

CM 1



CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-7-[(phenylmethyl)amino]-6-quinolinyl]- (9CI)
MF C44 H39 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-7-hydroxy-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-5-bromo-2-(methylamino)- (9CI)
MF C28 H30 Br N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Furancarboxylic acid, 1-acetyl-6-[(3,5-dibromobenzoyl)amino]-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-7-quinolinyl ester (9CI)
MF C32 H28 Br2 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide,
N-[1-acetyl-1,2,3,4-tetrahydro-5-hydroxy-4-(4-hydroxyphenyl)-7-methoxy-2,2,4-trimethyl-6-quinolinyl]- (9CI)
MF C34 H34 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-2-hydroxy- (9CI)
MF C27 H28 N2 O3

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Morpholinecarboxylic acid, 2-[[(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)amino]carbonyl]phenyl ester (9CI)
MF C32 H35 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-8-methoxy-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI)
MF C34 H34 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-4'-chloro- (9CI)
MF C33 H31 Cl N2 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-[[2-(dimethylamino)ethyl]amino]-2-oxoethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]- (9CI)
MF C39 H44 N4 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

























L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-4-(dimethylamino)- , (9CI)
MF C35 H44 N4 O4
CI COM

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-2-chloro-,
mono(trifluoroacetate)
(9CI)
MF C33 H38 Cl N3 O4 . C2 H F3 O2

CM 1

CM 2

$$\mathrm{F-\overset{F}{\underset{F}{C}}-CO_2H}$$

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetic acid,
[4-[1-acetyl-6-[([1,1'-biphenyl]-4-ylcarbonyl)amino]-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-quinolinyl]phenoxy]-, ethyl ester (9CI)
MF C37 H38 N2 O5

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-[(1-methylethyl)amino]-2-oxoethoxy]phenyl]-6-quinolinyl]-
(9CI)
MF C38 H41 N3 O4

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-(2-pyridinylmethoxy)phenyl]-6-quinolinyl]- (9CI)
MF C39 H37 N3 O3
CI COM

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-7-[(2-methylpropyl)amino]-4-phenyl-6-quinolinyl]-3,5-dibromo- (9CI)
MF C31 H35 Br2 N3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-7-(4-pyridinylmethoxy)-6-quinolinyl]-5-bromo-2-(methylamino)-,
mono(trifluoroacetate) (9CI)
MF C34 H35 Br N4 O3 . C2 H F3 O2

CM 1

CM 2

$$\mathrm{F-\overset{F}{\underset{F}{C}}-CO_2H}$$

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Morpholinecarboxamide, N-[3-[[1-acetyl-6-[([1,1'-biphenyl]-4-ylcarbonyl)amino]-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-7-quinolinyl]oxy]propyl]- (9CI)
MF C41 H46 N4 O5

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-5,7-dihydroxy-4-(4-hydroxyphenyl)-2,2,4-trimethyl-6-quinolinyl]- (9CI)
MF C33 H32 N2 O5

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-2-methoxy- (9CI)
MF C28 H30 N2 O3

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-2-[(2-oxo-5-oxazolidinyl)methoxy]- (9CI)
MF C31 H33 N3 O5

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4,7-tetramethyl-4-phenyl-6-quinolinyl)- (9CI)
MF C34 H34 N2 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI)
MF C33 H32 N2 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-3-bromo- (9CI)
MF C27 H27 Br N2 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-4-methoxy-3-methyl-,
mono(trifluoroacetate) (9CI)
MF C35 H43 N3 O5 . C2 H F3 O2

CM 1

CM 2

$$\mathrm{F-\overset{F}{\underset{F}{C}}-CO_2H}$$

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-2-chloro- (9CI)
MF C33 H38 Cl N3 O4
CI COM

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-[(2-furanylmethyl)amino]ethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-, mono(trifluoroacetate) (9CI)
MF C40 H41 N3 O4 . C2 H F3 O2

CM 1

PAGE 1-A



PAGE 2-A

CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN (Continued)

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetic acid, [4-[1-acetyl-6-[([1,1'-biphenyl]-4-ylcarbonyl)amino]-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-quinolinyl]phenoxy]- (9CI)
MF C35 H34 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[3-(4-morpholinyl)propoxy]phenyl]-6-quinolinyl]-, mono(trifluoroacetate) (9CI)
MF C40 H45 N3 O4 . C2 H F3 O2

CM 1



CM 2



L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Thiophenecarboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-7-[(3-pyridinylmethyl)amino]-6-quinolinyl]-5-methyl- (9CI)
MF C32 H34 N4 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-7-(3-pyridinylmethoxy)-6-quinolinyl]-5-bromo-2-(methylamino)- (9CI)
MF C34 H35 Br N4 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-7-(2-amino-2-oxoethoxy)-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl]- (9CI)
MF C35 H35 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-5-hydroxy-7-methoxy-4-(4-methoxyphenyl)-2,2,4-trimethyl-6-quinolinyl]- (9CI)
MF C35 H36 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-2-bromo- (9CI)
MF C22 H25 Br N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3-Isoxazolecarboxylic acid, 5-methyl-, 2-[[(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)amino]carbonyl]phenyl ester (9CI)
MF C32 H31 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Morpholineacetamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI)
MF C26 H33 N3 O3

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-3-bromo-2,6-dimethoxy- (9CI)
MF C29 H31 Br N2 O4

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[(4S)-1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl]- (9CI)
MF C33 H32 N2 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-4-methoxy-3-methyl- (9CI)
MF C35 H43 N3 O5
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-3,5-dibromo-, mono(trifluoroacetate) (9CI)
MF C33 H37 Br2 N3 O4 . C2 H F3 O2

CM 1



CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-[(2-furanylmethyl)amino]ethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]- (9CI)
MF C40 H41 N3 O4
CI COM

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



































































L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-7-(ethylamino)-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl]- (9CI)
MF C35 H37 N3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide,
N-[1-acetyl-7-[2-(diethylamino)ethoxy]-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl]-3,5-dimethyl- (9CI)
MF C35 H45 N3 O3
CI CCS

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-7-(4-pyridinylmethoxy)-6-quinolinyl]-, monohydrochloride (9CI)
MF C39 H37 N3 O3 . Cl H

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Thiophenecarboxamide,
N-[1-acetyl-1,2,3,4-tetrahydro-5-hydroxy-7-methoxy-4-(4-methoxyphenyl)-2,2,4-trimethyl-6-quinolinyl]-5-chloro- (9CI)
MF C27 H29 Cl N2 O5 S

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-2-bromo-3-methyl- (9CI)
MF C28 H29 Br N2 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Isoxazolesulfonic acid, 3,5-dimethyl-,
2-[[(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)amino]carbonyl]phenyl ester (9CI)
MF C32 H33 N3 O6 S

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-2-[[(2,4-difluorophenyl)methyl]amino]- (9CI)
MF C29 H31 F2 N3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-4-nitro- (9CI)
MF C27 H27 N3 O4

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-2-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI)
MF C33 H32 N2 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-4-bromo- (9CI)
MF C33 H38 Br N3 O4
CI CCS

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Morpholinecarboxamide, N-[3-[4-[1-acetyl-6-[(3,5-dichloro-2,6-dimethoxybenzoyl)amino]-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-quinolinyl]phenoxy]propyl]- (9CI)
MF C37 H44 Cl2 N4 O7

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [1-acetyl-1,2,3,4-tetrahydro-4-(4-hydroxyphenyl)-2,2,4-trimethyl-6-quinolinyl]-, 9H-fluoren-9-ylmethyl ester (9CI)
MF C35 H34 N2 O4

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-(2-amino-2-oxoethoxy)phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]- (9CI)
MF C35 H35 N3 O4

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-(dimethylamino)propoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]- (9CI)
MF C38 H43 N3 O3
CI CCS

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Thiophenecarboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-7-(propylamino)-6-quinolinyl]-5-methyl- (9CI)
MF C29 H35 N3 O2 S

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-7-[(5-methyl-3-isoxazolyl)methoxy]-4-phenyl-6-quinolinyl]-3,5-dimethyl- (9CI)
MF C34 H37 N3 O4

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-7-(3-pyridinylmethoxy)-6-quinolinyl]-, monohydrochloride (9CI)
MF C39 H37 N3 O3 . Cl H



L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-5,7-dimethoxy-4-(4-methoxyphenyl)-2,2,4-trimethyl-6-quinolinyl]-3,5-dichloro- (9CI)
MF C30 H32 Cl2 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-2-bromo-5-methoxy- (9CI)
MF C28 H29 Br N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-2-[(methylsulfonyl)oxy]- (9CI)
MF C28 H30 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanediamide,
N'-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-N-ethyl-N-(phenylmethyl)- (9CI)
MF C32 H37 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-4-(trifluoromethyl)- (9CI)
MF C28 H27 F3 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-3-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI)
MF C33 H32 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-2,3-dichloro-, mono(trifluoroacetate) (9CI)
MF C33 H37 Cl2 N3 O4 . C2 H F3 O2

CM 1



CM 2



L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(1-piperazinyl)ethoxy]phenyl]-6-quinolinyl]-, mono(trifluoroacetate) (9CI)
MF C39 H44 N4 O3 . C2 H F3 O2

CM 1



CM 2



L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [1-acetyl-1,2,3,4-tetrahydro-4-(4-methoxyphenyl)-2,2,4-trimethyl-6-quinolinyl]-, 9H-fluoren-9-ylmethyl ester (9CI)
MF C36 H36 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-(3-pyridinylmethoxy)phenyl]-6-quinolinyl]-, mono(trifluoroacetate) (9CI)
MF C39 H37 N3 O3 . C2 H F3 O2

CM 1



CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-(dimethylamino)ethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-, mono(trifluoroacetate) (9CI)
MF C37 H41 N3 O3 . C2 H F3 O2

CM 1



CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Furancarboxamide, N,N'-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6,7-quinolinediyl)bis- (9CI)
MF C30 H29 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide,
N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-7-[2-(1-pyrrolidinyl)ethoxy]-6-quinolinyl]-3,5-dimethyl-, mono(trifluoroacetate) (9CI)
MF C35 H43 N3 O3 . C2 H F3 O2

CM 1



CM 2



L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-7-(2-pyridinylmethoxy)-6-quinolinyl]-, monohydrochloride (9CI)
MF C39 H37 N3 O3 . Cl H



L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-5-hydroxy-7-methoxy-4-(4-methoxyphenyl)-2,2,4-trimethyl-6-quinolinyl]-3,5-dichloro- (9CI)
MF C29 H30 Cl2 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-phenylethyl)acetamide
MF C20 H21 N3 O2

L2 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)acetamide
MF C19 H19 N3 O2

L3 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)acetamide
MF C19 H19 N3 O2

L4 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)acetamide
MF C19 H19 N3 O2

L5 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)propanamide
MF C20 H21 N3 O2

L6 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)propanamide
MF C20 H21 N3 O2

L7 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)propanamide
MF C20 H21 N3 O2

L8 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)butanamide
MF C21 H23 N3 O2

L9 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)butanamide
MF C21 H23 N3 O2

L10 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)butanamide
MF C21 H23 N3 O2

L11 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)pentanamide
MF C22 H25 N3 O2

L12 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)pentanamide
MF C22 H25 N3 O2

L13 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)pentanamide
MF C22 H25 N3 O2

L14 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)hexanamide
MF C23 H27 N3 O2

L15 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)hexanamide
MF C23 H27 N3 O2

L16 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)hexanamide
MF C23 H27 N3 O2

L17 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)heptanamide
MF C24 H29 N3 O2

L18 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)heptanamide
MF C24 H29 N3 O2

L19 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)heptanamide
MF C24 H29 N3 O2

L20 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)octanamide
MF C25 H31 N3 O2

L21 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)octanamide
MF C25 H31 N3 O2

L22 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)octanamide
MF C25 H31 N3 O2

L23 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)nonanamide
MF C26 H33 N3 O2

L24 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)nonanamide
MF C26 H33 N3 O2

L25 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)nonanamide
MF C26 H33 N3 O2

L26 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)decanamide
MF C27 H35 N3 O2

L27 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)decanamide
MF C27 H35 N3 O2

L28 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)decanamide
MF C27 H35 N3 O2

L29 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)undecanamide
MF C28 H37 N3 O2

L30 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)undecanamide
MF C28 H37 N3 O2

L31 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)undecanamide
MF C28 H37 N3 O2

L32 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)dodecanamide
MF C29 H39 N3 O2

L33 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)dodecanamide
MF C29 H39 N3 O2

L34 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)dodecanamide
MF C29 H39 N3 O2

L35 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)tridecanamide
MF C30 H41 N3 O2

L36 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)tridecanamide
MF C30 H41 N3 O2

L37 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)tridecanamide
MF C30 H41 N3 O2

L38 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)tetradecanamide
MF C31 H43 N3 O2

L39 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)tetradecanamide
MF C31 H43 N3 O2

L40 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)tetradecanamide
MF C31 H43 N3 O2

L41 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)pentadecanamide
MF C32 H45 N3 O2

L42 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)pentadecanamide
MF C32 H45 N3 O2

L43 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)pentadecanamide
MF C32 H45 N3 O2

L44 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)hexadecanamide
MF C33 H47 N3 O2

L45 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)hexadecanamide
MF C33 H47 N3 O2

L46 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)hexadecanamide
MF C33 H47 N3 O2

L47 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)heptadecanamide
MF C34 H49 N3 O2

L48 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)heptadecanamide
MF C34 H49 N3 O2

L49 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)heptadecanamide
MF C34 H49 N3 O2

L50 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)octadecanamide
MF C35 H51 N3 O2

L51 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)octadecanamide
MF C35 H51 N3 O2

L52 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)octadecanamide
MF C35 H51 N3 O2

L53 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)nonadecanamide
MF C36 H53 N3 O2

L54 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)nonadecanamide
MF C36 H53 N3 O2

L55 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)nonadecanamide
MF C36 H53 N3 O2

L56 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)eicosanamide
MF C37 H55 N3 O2

L57 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)eicosanamide
MF C37 H55 N3 O2

L58 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)eicosanamide
MF C37 H55 N3 O2

L59 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)heneicosanamide
MF C38 H57 N3 O2

L60 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)heneicosanamide
MF C38 H57 N3 O2

L61 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)heneicosanamide
MF C38 H57 N3 O2

L62 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)docosanamide
MF C39 H59 N3 O2

L63 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)docosanamide
MF C39 H59 N3 O2

L64 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)docosanamide
MF C39 H59 N3 O2

L65 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)tricosanamide
MF C40 H61 N3 O2

L66 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)tricosanamide
MF C40 H61 N3 O2

L67 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)tricosanamide
MF C40 H61 N3 O2

L68 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)tetracosanamide
MF C41 H63 N3 O2

L69 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)tetracosanamide
MF C41 H63 N3 O2

L70 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)tetracosanamide
MF C41 H63 N3 O2

L71 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)pentacosanamide
MF C42 H65 N3 O2

L72 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)pentacosanamide
MF C42 H65 N3 O2

L73 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)pentacosanamide
MF C42 H65 N3 O2

L74 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)hexacosanamide
MF C43 H67 N3 O2

L75 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)hexacosanamide
MF C43 H67 N3 O2

L76 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)hexacosanamide
MF C43 H67 N3 O2

L77 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)heptacosanamide
MF C44 H69 N3 O2

L78 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)heptacosanamide
MF C44 H69 N3 O2

L79 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)heptacosanamide
MF C44 H69 N3 O2

L80 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)octacosanamide
MF C45 H71 N3 O2

L81 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)octacosanamide
MF C45 H71 N3 O2

L82 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)octacosanamide
MF C45 H71 N3 O2

L83 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)nonacosanamide
MF C46 H73 N3 O2

L84 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)nonacosanamide
MF C46 H73 N3 O2

L85 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)nonacosanamide
MF C46 H73 N3 O2

L86 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)triacontanamide
MF C47 H75 N3 O2

L87 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)triacontanamide
MF C47 H75 N3 O2

L88 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)triacontanamide
MF C47 H75 N3 O2

L89 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)hentriacontanamide
MF C48 H77 N3 O2

L90 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)hentriacontanamide
MF C48 H77 N3 O2

L91 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)hentriacontanamide
MF C48 H77 N3 O2

L92 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)dotriacontanamide
MF C49 H79 N3 O2

L93 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)dotriacontanamide
MF C49 H79 N3 O2

L94 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)dotriacontanamide
MF C49 H79 N3 O2

L95 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)tritriacontanamide
MF C50 H81 N3 O2

L96 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)tritriacontanamide
MF C50 H81 N3 O2

L97 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)tritriacontanamide
MF C50 H81 N3 O2

L98 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(4-methylphenyl)tetratriacontanamide
MF C51 H83 N3 O2

L99 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(2-methylphenyl)tetratriacontanamide
MF C51 H83 N3 O2

L100 317 ANSWER CONTINUED 2007 ACS on STN
IN 2-[4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridazin-1-yl]-N-(3-methylphenyl)tetratriacontanamide
MF C51 H83 N3 O2

























L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanediamide,
N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-N'-[(4-methoxyphenyl)methyl]- (9CI)
MF C31 H35 N3 O4

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-2-(1,1-dimethylethoxy)- (9CI)
MF C26 H34 N2 O3

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-4-chloro- (9CI)
MF C27 H27 Cl N2 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-4-(1,1-dimethylethyl)-, mono(trifluoroacetate) (9CI)
MF C37 H47 N3 O4 . C2 H F3 O2

CM 1

CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-[(2-aminoethyl)amino]ethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-, mono(trifluoroacetate) (9CI)
MF C37 H42 N4 O3 . C2 H F3 O2

CM 1

CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide,
N-[1-acetyl-4-[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-, mono(trifluoroacetate) (9CI)
MF C41 H47 N3 O3 . C2 H F3 O2

CM 1

CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]-6-quinolinyl]- (9CI)
MF C39 H41 N3 O5

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Thiophenecarboxamide,
N-[1-acetyl-7-(dimethylamino)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-6-quinolinyl]-5-chloro- (9CI)
MF C25 H26 Cl N3 O2 S

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Cyclopentanecarboxamide,
N-[1-acetyl-7-(dimethylamino)-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl]- (9CI)
MF C28 H37 N3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-7-[2-(dimethylamino)-2-oxoethoxy]-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl]- (9CI)
MF C37 H39 N3 O4

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-7-hydroxy-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-3,5-dichloro- (9CI)
MF C27 H26 Cl2 N2 O3

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Furancarboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-5-hydroxy-7-methoxy-4-(4-methoxyphenyl)-2,2,4-trimethyl-6-quinolinyl]- (9CI)
MF C27 H30 N2 O6

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-4-(4-hydroxyphenyl)-2,2,4-trimethyl-6-quinolinyl]- (9CI)
MF C33 H32 N2 O3

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanoic acid,
3-[(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)amino]-3-oxo-, ethyl ester (9CI)
MF C25 H30 N2 O4

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide,
2-(acetylamino)-N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-5-bromo- (9CI)
MF C29 H30 Br N3 O3

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, (1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-, 1,1-dimethylethyl ester (9CI)
MF C25 H32 N2 O3

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-7-(2-pyridinylmethoxy)-6-quinolinyl]- (9CI)
MF C39 H37 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-4-(1,1-dimethylethyl)- (9CI)
MF C37 H47 N3 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-[(2-aminoethyl)amino]ethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]- (9CI)
MF C37 H42 N4 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(methylamino)-2-oxoethoxy]phenyl]-6-quinolinyl]- (9CI)
MF C36 H37 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]- (9CI)
MF C41 H47 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Thiophenecarboxamide, N-[1-acetyl-7-(dimethylamino)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-6-quinolinyl]-5-bromo- (9CI)
MF C25 H26 Br N3 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-7-(dimethylamino)-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl]-3,5-dibromo- (9CI)
MF C29 H31 Br2 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-7-(4-pyridinylmethoxy)-6-quinolinyl]-3,5-dichloro-, mono(trifluoroacetate) (9CI)
MF C33 H31 Cl2 N3 O3 . C2 H F3 O2

CM 1



CM 2



L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-7-hydroxy-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI)
MF C33 H32 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-5,7-dimethoxy-4-(4-methoxyphenyl)-2,2,4-trimethyl-6-quinolinyl]- (9CI)
MF C36 H38 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-4-(2-methoxyphenyl)-2,2,4-trimethyl-6-quinolinyl]- (9CI)
MF C34 H34 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 2-(acetyloxy)-N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI)
MF C29 H30 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tricyclo[3.3.1.13,7]decane-1-propanamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI)
MF C33 H42 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-2,2,2-trifluoro- (9CI)
MF C22 H23 F3 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-7-(4-pyridinylmethoxy)-6-quinolinyl]- (9CI)
MF C39 H37 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-, mono(trifluoroacetate) (9CI)
MF C33 H39 N3 O4 . C2 H F3 O2

CM 1



CM 2



L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide,
N-[1-acetyl-1,2,3,4-tetrahydro-4-[4-[2-[(2-hydroxyethyl)amino]ethoxy]phenyl]-2,2,4-trimethyl-6-quinolinyl]-, mono(trifluoroacetate) (salt) (9CI)
MF C37 H41 N3 O4 . C2 H F3 O2

CM 1



CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-[[2-(dimethylamino)ethyl]amino]-2-oxoethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-, monohydrochloride (9CI)
MF C39 H44 N4 O4 . Cl H



● HCl

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Morpholinecarboxamide, N-[3-[4-[1-acetyl-6-[([1,1'-biphenyl]-4-ylcarbonyl)amino]-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-quinolinyl]phenoxy]propyl]- (9CI)
MF C41 H46 N4 O4

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [1-acetyl-7-(dimethylamino)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-6-quinolinyl]-, 9H-fluoren-9-ylmethyl ester (9CI)
MF C35 H35 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-7-(dimethylamino)-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl]- (9CI)
MF C35 H37 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-7-(4-pyridinylmethoxy)-6-quinolinyl]-3,5-dichloro- (9CI)
MF C31 H31 Cl2 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-7-[2-(4-morpholinyl)ethoxy]-4-phenyl-6-quinolinyl]-, monohydrochloride (9CI)
MF C39 H43 N3 O4 . Cl H



● HCl

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Thiophenecarboxamide,
N-[1-acetyl-1,2,3,4-tetrahydro-5,7-dimethoxy-4-(4-methoxyphenyl)-2,2,4-trimethyl-6-quinolinyl]-5-bromo- (9CI)
MF C28 H31 Br N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-2-[(cyclopropylmethyl)amino]- (9CI)
MF C26 H33 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-3,5-dichloro-2,6-dimethoxy- (9CI)
MF C29 H30 Cl2 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Butanamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-3-methyl- (9CI)
MF C25 H32 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-(4-methylphenyl)-6-quinolinyl]-4-nitro- (9CI)
MF C28 H29 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-7-(3-pyridinylmethoxy)-6-quinolinyl]- (9CI)
MF C37 H35 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]- (9CI)
MF C33 H39 N3 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide,
N-[1-acetyl-1,2,3,4-tetrahydro-4-[4-[2-[(2-hydroxyethyl)amino]ethoxy]phenyl]-2,2,4-trimethyl-6-quinolinyl]- (9CI)
MF C37 H41 N3 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-oxo-2-[(phenylmethyl)amino]ethoxy]phenyl]-6-quinolinyl]- (9CI)
MF C42 H41 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-(4-pyridinylmethoxy)phenyl]-6-quinolinyl]-, mono(trifluoroacetate) (9CI)
MF C39 H37 N3 O3 . C2 H F3 O2

CM 1



CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, (1-acetyl-7-amino-1,2,3,4-tetrahydro-4-methyl-4-phenyl-6-quinolinyl)-, 9H-fluoren-9-ylmethyl ester (9CI)
MF C33 H31 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Thiophenecarboxamide, N-[1-acetyl-7-(dimethylamino)-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl]-5-methyl- (9CI)
MF C28 H33 N3 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-7-(2-furanylmethoxy)-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl]-3,5-dimethyl- (9CI)
MF C34 H36 N2 O4





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-5,7-dimethoxy-4-(4-methoxyphenyl)-2,2,4-trimethyl-6-quinolinyl]-3,5-dibromo- (9CI)
MF C30 H32 Br2 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Furancarboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-5,7-dimethoxy-4-(4-methoxyphenyl)-2,2,4-trimethyl-6-quinolinyl]-4,5-dimethyl- (9CI)
MF C30 H36 N2 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanoic acid, 3-[(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)amino]-3-oxo-, 2-furanylmethyl ester (9CI)
MF C28 H30 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-3,4,5-trimethoxy- (9CI)
MF C30 H34 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Furancarboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI)
MF C25 H26 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, N-[1-acetyl-4-(4-hexylphenyl)-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-2,2,2-trifluoro- (9CI)
MF C28 H35 F3 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-7-[2-(4-morpholinyl)ethoxy]-4-phenyl-6-quinolinyl]- (9CI)
MF C39 H43 N3 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-5-methyl-2-nitro-, mono(trifluoroacetate) (9CI)
MF C34 H40 N4 O6 . C2 H F3 O2

CM 1



CM 2



L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-[(3-pyridinylmethyl)amino]ethoxy]phenyl]-6-quinolinyl]-, mono(trifluoroacetate) (9CI)
MF C41 H42 N4 O3 . C2 H F3 O2

CM 1

PAGE 1-A



PAGE 2-A



CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN (Continued)



L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-4-[4-[2-[(2-methoxyethyl)amino]-2-oxoethoxy]phenyl]-2,2,4-trimethyl-6-quinolinyl]- (9CI)
MF C39 H43 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-(4-pyridinylmethoxy)phenyl]-6-quinolinyl]- (9CI)
MF C39 H37 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT













L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, (1-acetyl-1,2,3,4-tetrahydro-4-methyl-7-nitro-4-phenyl-6-quinolinyl)-, 9H-fluoren-9-ylmethyl ester (9CI)
MF C33 H29 N3 O5

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [1-acetyl-7-(dimethylamino)-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl]-, 9H-fluoren-9-ylmethyl ester (9CI)
MF C37 H39 N3 O3

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-7-hydroxy-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-3,5-dimethyl- (9CI)
MF C29 H32 N2 O3

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-5-hydroxy-7-methoxy-4-(4-methoxyphenyl)-2,2,4-trimethyl-6-quinolinyl]-3,5-dibromo- (9CI)
MF C29 H30 Br2 N2 O5

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-5,7-dimethoxy-4-(4-methoxyphenyl)-2,2,4-trimethyl-6-quinolinyl]-3-chloro-2,6-dimethoxy-
(9CI)
MF C32 H37 Cl N2 O7

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanoic acid,
3-[(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)amino]-3-oxo-, 2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl ester (9CI)
MF C30 H39 N3 O6

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-5-bromo-2-(methylamino)- (9CI)
MF C28 H30 Br N3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzenepropanamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI)
MF C29 H32 N2 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-(4-methylphenyl)-6-quinolinyl]-2,2,2-trifluoro- (9CI)
MF C23 H25 F3 N2 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-3-nitro-, mono(trifluoroacetate) (9CI)
MF C33 H38 N4 O6 . C2 H F3 O2

CM 1

CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-5-methyl-2-nitro- (9CI)
MF C34 H40 N4 O6
CI COM

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-[(3-pyridinylmethyl)amino]ethoxy]phenyl]-6-quinolinyl]-
(9CI)
MF C41 H42 N4 O3
CI COM

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-[(2-furanylmethyl)amino]-2-oxoethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]- (9CI)
MF C40 H39 N3 O5

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-(diethylamino)ethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-, mono(trifluoroacetate) (9CI)
MF C39 H45 N3 O3 . C2 H F3 O2

CM 1

CM 2

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, (1-acetyl-1,2,3,4-tetrahydro-4-methyl-4-phenyl-6-quinolinyl)-, 9H-fluoren-9-ylmethyl ester (9CI)
MF C33 H30 N2 O3

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, (1-acetyl-7-amino-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-, 9H-fluoren-9-ylmethyl ester (9CI)
MF C35 H35 N3 O3

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [3-[[1-acetyl-4-[(3,4-dimethylbenzoyl)amino]-1,2,3,4-tetrahydro-2,2,6-trimethyl-4-phenyl-7-quinolinyl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI)
MF C34 H43 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-3,3-dimethoxy-4-(4-methoxyphenyl)-2,2,6-trimethyl-6-quinolinyl]-3,5-dimethyl- (9CI)
MF C32 H36 N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 4-nitro-N-[3,3,3,4-tetrahydro-2,2,4-trimethyl-6-[[4-methoxyphenyl]-6-quinolinyl]- (9CI)
MF C29 H31 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanoic acid, 3-[[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-[(2-quinolinyl)amino]-3-quin-, (2-oxo-1-pyrrolidinyl)methyl ester (9CI)
MF C34 H33 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl]-3,5-dimethoxy- (9CI)
MF C27 H28 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 4-[[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-(4-methylphenoxy)-6-quinolinyl]- (9CI)
MF C29 H30 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

L5 237 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 6-Quinolinamine, 1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-[(phenylmethoxy)methyl]- (9CI)
MF C27 H30 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> file caplus
FILE 'CAPLUS' ENTERED AT 16:55:47 ON 03 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Jul 2007 VOL 147 ISS 2
FILE LAST UPDATED: 2 Jul 2007 (20070702/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

(FILE 'HOME' ENTERED AT 16:51:11 ON 03 JUL 2007)

FILE 'REGISTRY' ENTERED AT 16:51:33 ON 03 JUL 2007
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 STRUCTURE UPLOADED
L4 1 S L3
L5 237 S L3 FULL

FILE 'CAPLUS' ENTERED AT 16:55:47 ON 03 JUL 2007

=> s l5
L6 5 L5

=> d cbib abs hitstr

10540336.trn

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
2003:906031 Document No. 141:355434 First page of report on PNR receptor antagonistic activity: Quantitative investigations on phenyl-substituted and structural features among 4-amino-4-phenyltetrahydroquinoline derivatives.
Malviyaman, S.; Prasanna, S. (School of Pharmacy, Devi Ahilya Vishwavidyalaya, Indore, 452017, India). Bioorganic & Medicinal Chemistry Letters, 13(20), 4496-4501 (English) 2003. CODEN: BMCLE8. ISSN: 0960-894X. Publisher: Elsevier B.V.
AB A quest, attempt has been made to correlate the structure-activity relationship (SAR) among the recently reported 4-amino-4-phenyltetrahydroquinoline derivs. as antagonists for the G-protein-coupled human PNR receptor. The compds. used for the present study have been reported to show high antagonistic efficacy in vitro using a CHO-hPNR(flex) assay. Our CoMFA investigations revealed a hydrophobic type of interactions between these ligands and the PNR receptor, hence confirming the presence of a lipophilic pocket on the active site of the target structure. The poo. coefficient of C log P variable in our derived QSAR model supports that more hydrophobic ligands are crucial for their PNR receptor antagonistic affinity. In exploring the structural requirements among these congeners, the authors found an amide linkage as conducive to their PNR receptor antagonistic activity. Also, an unsubstituted 4-Ph ring of the tetrahydroquinoline scaffold is favorable for their PNR receptor antagonistic activity. The results discussed herein would be useful in understanding the nature of interactions of these newly identified ligands as PNR receptor antagonists and in designing more potent ligands based on this novel 4-amino-4-phenyltetrahydroquinoline scaffold.
IT 497064-29-9 497064-31-3 497064-33-5
497064-35-7 497064-41-5 497064-44-8
497064-72-2 497064-73-3 497064-75-5
754993-66-3 754993-02-7 754993-03-8
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(QSAR of 4-amino-4-phenyltetrahydroquinoline derivs. as PNR receptor antagonists)
RN 497064-29-9 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl]-4-chloro- (9CI) (CA INDEX NAME)

RN 497064-31-3 CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 497064-44-8 CAPLUS
CN 3-Furancarboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)

RN 497064-73-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4,7-tetramethyl-4-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)



RN 497064-75-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-(4-methylphenyl)-6-quinolinyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 497064-33-5 CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 497064-35-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)



RN 497064-41-5 CAPLUS
CN 6-Quinolinamine, 1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-N-(phenylmethoxymethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 754993-66-3 CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-3-[(1,1-dimethylethoxy)methyl]- (9CI) (CA INDEX NAME)



RN 754993-02-7 CAPLUS
CN [1,1'-Biphenyl]-3-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)



RN 754993-03-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

=> d cbib abs hitstr 1-5

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
2005:[illegible] Document No. 143:[illegible] First QSAR report on FSH receptor antagonistic activity: Quantitative investigations on physico-chemical and structural features among 6-amino-4-phenyltetrahydroquinoline derivatives. Manivannan, E.; Prasanna, S. (School of Pharmacy, Devi Ahilya Vishwavidyalaya, Indore, 452017, India). Bioorganic & Medicinal Chemistry Letters, 15(20), 4496-4501 (English) 2005. CODEN: BMCLE8. ISSN: 0960-894X. Publisher: Elsevier B.V.

AB A QSAR attempt has been made to correlate the structure-activity relationship (SAR) among the recently reported 6-amino-4-phenyltetrahydroquinoline derivs. as antagonists for the Gs-protein-coupled human FSH receptor. The compds. used for the present study have been reported to show high antagonistic efficacy in vitro using a CHO-hFSHR(luc) assay. Our QSAR investigations revealed a hydrophobic type of interactions between these ligands and the FSH receptor, hence confirming the presence of a lipophilic pocket on the active site of the target structure. The pos. coefficient of C log P variable in our derived QSAR model suggests that more hydrophobic ligands are crucial for their FSH receptor antagonistic efficacy. In exploring the structural requirements among these congeners, the authors found an amide linkage as conducive to their FSH receptor antagonistic activity. Also, an unsubstituted 4-Ph ring of the tetrahydroquinoline scaffold is favorable for their FSH receptor antagonistic activity. The results discussed herein would be useful in understanding the nature of interactions of these newly identified ligands as FSH receptor antagonists and in designing more potent ligands based on this novel 6-amino-4-phenyltetrahydroquinoline scaffold.

IT 487064-[illegible] 487064-[illegible] 487064-[illegible]
487064-[illegible] 487064-[illegible] 487064-[illegible]
487064-[illegible] 487064-[illegible] 487064-[illegible]
754993-[illegible] 754993-[illegible] 754993-[illegible]
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(QSAR of 6-amino-4-phenyltetrahydroquinoline derivs. as FSH receptor antagonists)

RN 487064-19-9 CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-4-chloro- (9CI) (CA INDEX NAME)



RN 487064-[illegible] CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
quinolinyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 487064-[illegible] CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 487064-[illegible] CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)



RN 487064-[illegible] CAPLUS
CN 6-Quinolinamine, 1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-N-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 487064-[illegible] CAPLUS
CN 2-Furancarboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)

RN 487064-[illegible] CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4,7-tetramethyl-4-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)



RN 487064-[illegible] CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-8-methoxy-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)

RN 487064-[illegible] CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-(4-methylphenyl)-6-quinolinyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 754993-[illegible] CAPLUS
CN Acetamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-2-(1,1-dimethylethoxy)- (9CI) (CA INDEX NAME)



RN 754993-[illegible] CAPLUS
CN [1,1'-Biphenyl]-3-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)



RN 754993-[illegible] CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
2004:[illegible] Document No. 142:[illegible] Identification of Substituted 6-Amino-4-phenyltetrahydroquinoline Derivatives: Potent Antagonists for the Follicle-Stimulating Hormone Receptor. van Straten, Nicole C. R.; van Berkel, Theo H. J.; Demont, Dennis R.; Karstens, Willem-Jan F.; Merkx, Remco; Oosterom, Julia; Schulz, Juergen; van Someren, Richard G.; Timmers, Cornelis M.; van Zandvoort, Peter M. (Lead Discovery Unit, Research and Development, Oss, 5340, Neth.). Journal of Medicinal Chemistry, 48(6), 1697-1700 (English) 2005. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT [illegible]. Publisher: American Chemical Society.

AB Substituted 6-amino-4-phenyl-tetrahydroquinoline derivs. are described that are antagonists for the Gs-protein-coupled human FSH receptor. These compds. show high antagonistic efficacy in vitro using a CHO cell line expressing the human FSH receptor. Antagonist 10 also showed a submicromolar IC50 in a more physiol. relevant rat granulosa cell assay and was found to significantly inhibit follicle growth and ovulation in an ex vivo mouse model. This compound class may open the way toward a novel, nonsteroidal approach for contraception.

IT 487064-[illegible]P 487064-[illegible]P 487064-[illegible]P
487064-[illegible]P 487064-[illegible]P 487064-[illegible]P
487064-[illegible]P 487064-[illegible]P 487064-[illegible]P
754993-[illegible]P 754993-[illegible]P 754993-[illegible]P
754993-[illegible]P 754993-[illegible]P 754993-[illegible]P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(structure activity relationships of aminophenyltetrahydroquinoline derivs. as antagonists for FSH receptor)

RN 487064-[illegible] CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-4-chloro- (9CI) (CA INDEX NAME)



RN 487064-[illegible] CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 487064-[illegible] CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 487064-[illegible] CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)



RN 487064-[illegible] CAPLUS
CN 6-Quinolinamine, 1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-N-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)

RN 487064-[illegible] CAPLUS
CN 2-Furancarboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 487064-[illegible] CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4,7-tetramethyl-4-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)



RN 487064-[illegible] CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-8-methoxy-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)



RN 487064-[illegible] CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-(4-methylphenyl)-6-quinolinyl]- (9CI) (CA INDEX NAME)

10540336.trn

10540336.trn



L6 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 717856-93-3 CAPLUS
CN Carbamic acid, [3-acetyl-7-(dimethylamino)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-6-quinolinyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
2004:346403 Document No. 140:346262 Preparation of tetrahydroquinoline derivatives for fertility regulation. Timmers, Cornelis Marinus; Kerstens, Willem Frederik Johan (Akzo Nobel N.V., Neth.). PCT Int. Appl. WO 2004034779 A2 20040429, 23 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2003-EP11023 20031006. PRIORITY: EP 2002-102779 20021230; EP 2003-102945 20031006.

GI



AB Title compds. I [wherein R1, R2 = H, Me; R3 = heterocyclylalkylalkyl, (heterocyclylalkyl)alkyl, (dialkylaminocarbonylaminoalkyl, etc.; R4 = (heterocyclyl, (heterocyclo)alkyl, alkyl; and pharmaceutically acceptable salts thereof] were prepared For example, II, I (R1 = R2 = Me, R3 = NHCH2CH2Ph), R4 = biphenyl, was given in multiple-step synthesis starting from (3,3,5-trimethyl-1,3-dihydroquinolin-6-yl)carbamic acid tert-Bu ester. The prepared title compds. (exhibited an IC50 value of less than 10-7 M in either an agonistic or an antagonistic assay for CRH-R2 bioactivity. These I and their pharmaceutical compns. are useful for the manufacture of a medicament for fertility regulation.

IT 717065-74-1D 717065-76-6D 717065-96-0D
717065-82-2D 717065-84-4P 717065-86-6D
717065-88-8P 717065-89-9P 717065-91-2D
717065-93-4P 717065-94-5P 717065-95-7D
717065-99-2D 717066-00-7P 717066-01-8P
717066-03-0P 717066-04-1P 717066-09-6P
717066-10-9D
717066-12-0P 717066-14-2P 717066-16-4D
717066-18-6P 717066-20-0P 717066-21-1P
717066-23-8P 717066-25-0D
717066-27-2P 717066-29-4P 717066-30-7P
717066-32-9P 717066-34-1P 717066-36-3P
717066-38-5P 717066-40-9P 717066-42-7P 717066-44-9P

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CN 1

CRN 76-05-1
CMF C2 H F3 O2

RN 717065-82-2 CAPLUS
CN (1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-[[1-methyl-3-(phenylmethyl)-4-piperidinyl]methoxy]phenyl]-6-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CN 1

CRN 717065-81-1
CMF C39 H37 N3 O2

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CN 1

CRN 76-05-1
CMF C2 H F3 O2

RN 717065-84-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-[[1-methyl-3-piperidinyl]methoxy]phenyl]-6-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CN 1

CRN 717065-83-3
CMF C40 H43 N3 O2

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CN 1

CRN 76-05-1
CMF C2 H F3 O2



RN 717065-66-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-(diethylamino)ethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CN 1

CRN 717065-65-9
CMF C39 H42 N3 O2

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CN 1

CRN 76-05-1
CMF C2 H F3 O2

RN 717065-76-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-[(1-methylethyl)amino]-1-oxoethoxy]phenyl]-6-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CN 1

CRN 717065-75-1
CMF C39 H43 N3 O3

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CN 1

CRN 76-05-1
CMF C2 H F3 O2

RN 717065-69-9 CAPLUS
CN 4-Morpholinecarboxamide, 8-[3-[4-[[[1,1'-Biphenyl]-4-yl]methyl]amino]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]phenoxy]propyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 717065-91-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[3-(3-morpholinyl)propoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CN 1

CRN 717065-90-1
CMF C41 H47 N3 O3

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 2

CRN 76-05-1
CMF C2 H F3 O2

RN 717065-93-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[(3-aminopropyl)amino]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 2

CRN 76-05-1
CMF C2 H F3 O2

RN 717065-94-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[(3-amino-2-oxopropyl)amino]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]- (9CI) (CA INDEX NAME)

RN 717065-95-7 CAPLUS

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-[(dimethylamino)-2-oxoethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]- (9CI) (CA INDEX NAME)

RN 717065-93-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-4-[4-[2-(1-pyrrolidinylmethyl)phenoxy]phenyl]-2,2,4-trimethyl-6-quinolinyl]-

CN 2

CRN 76-05-1
CMF C2 H F3 O2

RN 717065-96-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-(1-pyrrolidinylmethyl)phenoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A

PAGE 2-A

CN 2

CRN 76-05-1
CMF C2 H F3 O2

RN 717065-97-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-[(2-methoxyethyl)amino]-2-oxoethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CN 2

CRN 76-05-1
CMF C2 H F3 O2

RN 717066-02-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(1-pyrrolidinylmethyl)phenoxy]ethoxy]phenyl]-6-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 2

CRN 76-05-1
CMF C2 H F3 O2

RN 717066-03-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(1-pyrrolidinylmethyl)phenoxy]ethoxy]phenyl]-6-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CN 1

CRN 717066-01-0
CMF C39 H43 N3 O4

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 2

CRN 76-05-1
CMF C2 H F3 O2

RN 717065-98-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[3-[(2-methoxyethyl)amino]-2-oxoethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A

PAGE 2-A

CN 2

CRN 76-05-1
CMF C2 H F3 O2

RN 717066-01-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[3-[(2-methoxyethyl)amino]-2-oxoethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 2

CRN 76-05-1
CMF C2 H F3 O2

RN 717066-04-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-4-[4-[2-[(2-methoxyethyl)amino]-2-oxoethoxy]phenyl]-2,2,4-trimethyl-6-quinolinyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 717066-05-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-oxo-2-[(phenylmethyl)amino]ethoxy]phenyl]-6-quinolinyl]- (9CI) (CA INDEX NAME)



RN 717066-06-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-[[2-(dimethylamino)ethyl]amino]-2-oxoethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

RN 717066-07-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(methylamino)-2-oxoethoxy]phenyl]-6-quinolinyl]- (9CI) (CA INDEX NAME)



RN 717066-08-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]-6-quinolinyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 717066-09-6 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[3-(4-morpholinyl)propoxy]phenyl]-6-quinolinyl]-5-bromo-2-(methylamino)- (9CI) (CA INDEX NAME)



RN 717066-14-3 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[3-(4-morpholinyl)propoxy]phenyl]-6-quinolinyl]-3,5-dichloro-2,6-dimethoxy- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 717066-16-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-[(2-furanylmethyl)amino]ethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 717066-15-4
CMF C41 H41 N3 O4

PAGE 1-A



L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 717066-21-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide,
N-[1-acetyl-1,2,3,4-tetrahydro-4-[4-[2-[(2-hydroxy-1,1-dimethylethyl)amino]ethoxy]phenyl]-2,2,4-trimethyl-6-quinolinyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 717066-20-1
CMF C39 H45 N3 O4



CM 2

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 76-05-1
CMF C2 H F3 O2

RN 717066-23-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-[(3-pyridinylmethyl)amino]ethoxy]phenyl]-6-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 717066-22-3
CMF C41 H42 N4 O3

PAGE 1-A



L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 717066-25-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide,
N-[1-acetyl-1,2,3,4-tetrahydro-4-[4-[2-[(2-hydroxyethyl)amino]ethoxy]phenyl]-2,2,4-trimethyl-6-quinolinyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 717066-24-5
CMF C37 H41 N3 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 717066-27-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-4-[4-[2-[(2-aminoethyl)amino]ethoxy]phenyl]-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 717066-26-7
CMF C37 H42 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 717066-29-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(1-piperazinyl)ethoxy]phenyl]-6-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 717066-28-9
CMF C39 H44 N4 O3

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 717066-30-3 CAPLUS
CN 4-Morpholinebutanamide, N-[3-[4-[1-acetyl-6-[(3,5-dichloro-2,6-dimethoxybenzoyl)amino]-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-quinolinyl]phenoxy]propyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 717066-33-6 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-3,5-dibromo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 717066-32-5
CMF C33 H37 Br2 N3 O4

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 717066-36-9 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-2-chloro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 717066-35-8
CMF C33 H38 Cl N3 O4

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 717066-38-1 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-3,5-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 717066-37-0
CMF C35 H43 N3 O4

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 717066-40-5 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-2,5-dichloro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 717066-39-2
CMF C33 H37 Cl2 N3 O4

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 717066-42-7 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-2-methyl-5-nitro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 717066-41-6
CMF C34 H40 N4 O6

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 717066-44-9 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 717066-43-8
CMF C33 H39 N3 O4

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 717066-46-1 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-4-(1,1-dimethylethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 717066-45-0
CMF C37 H47 N3 O4

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 717066-46-3 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-2,3-dichloro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 717066-07-2
CMF C33 H37 Cl2 N3 O4

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 717066-50-7 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-4-bromo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 717066-09-4
CMF C33 H38 Br N3 O4

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 717066-52-9 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-4-methoxy-3-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 717066-11-8
CMF C35 H43 N3 O5

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 717066-54-1 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-4-(dimethylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 717066-13-0
CMF C35 H44 N4 O4

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 717066-56-3 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 717066-15-2
CMF C34 H38 F3 N3 O4

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 717066-58-5 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-6-quinolinyl]-3-nitro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 717066-17-4
CMF C33 H38 N4 O6

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 467064-85-7P 467065-23-6P 717065-96-8P
717065-97-9P 717066-11-8P 717066-13-1P
717066-17-6P 717066-19-7P 717066-29-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1-acetyl-2,2,4-trimethyl-4-phenylquinoline derivs. for fertility regulation)
RN 467064-79-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-4-(4-hydroxyphenyl)-2,2,4-trimethyl-6-quinolinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 467065-23-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-4-(4-methoxyphenyl)-2,2,4-trimethyl-6-quinolinyl]- (9CI) (CA INDEX NAME)



RN 717065-96-8 CAPLUS
CN Acetic acid, [4-[1-acetyl-6-[([1,1'-biphenyl]-4-ylcarbonyl)amino]-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-quinolinyl]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 717065-97-9 CAPLUS
CN Acetic acid, [4-[1-acetyl-6-[([1,1'-biphenyl]-4-ylcarbonyl)amino]-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-quinolinyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 717066-11-8 CAPLUS
CN Carbamic acid, [1-acetyl-1,2,3,4-tetrahydro-4-(4-methoxyphenyl)-2,2,4-trimethyl-6-quinolinyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)



RN 717066-13-1 CAPLUS
CN Carbamic acid, [1-acetyl-1,2,3,4-tetrahydro-4-(4-hydroxyphenyl)-2,2,4-trimethyl-6-quinolinyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 717066-17-6 CAPLUS
CN Acetic acid, [4-[1-acetyl-6-[([1,1'-biphenyl]-4-ylcarbonyl)amino]-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-quinolinyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 717066-19-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-4-[4-(2-hydroxyethoxy)phenyl]-2,2,4-trimethyl-6-quinolinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 717066-29-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-[4-[2-[(methylsulfonyl)oxy]ethoxy]phenyl]-6-quinolinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
2003:41109 Document No. 138:106606 Preparation of tetrahydroquinoline derivatives and use thereof to control fertility. Van Straten, Nicole Corine Renee; Van Someren, Rudolf Gijsbertus; Schulz, Jurgen (Akzo Nobel N.V., Neth.). PCT Int. Appl. WO 2003004028 A1 20030116, 70 pp. DESIGNATED STATES: W: [illegible]. (English). CODEN: PIXXD2. APPLICATION: WO 2002-EP7022 20020625. PRIORITY: EP 2001-202121 20010702.
GI



AB Tetrahydroquinoline derivs. (I; wherein R1 = formyl, (C1-C6)alkylcarbonyl, (C1-C6)alkylsulfonyl; R2, R3, independently = H, (C1-C4)alkyl; R4 = phenyl; R5 = (C1-C4)alkyl; Y-X = [illegible], etc., or Y-X is a bond; R6 = H, trifluoromethyl, (C1-C6)alkyl, 1- or 2-adamantyl(C1-C4)alkyl, (C2-C6)alkenyl, (C3-C8)heteroaryl, (C3-C8)cycloalkyl, (C2-C6)heterocycloalkyl, (C1-C4)alkylthio(C1-C4)alkyl, etc.; R7 = H, (C1-C4)alkyl, (C1-C4)alkoxy, halo, trifluoromethyl, cyano, nitro, hydroxy), etc.] were prepared. For example, 1-acetyl-6-(tert-butoxycarbonyl)amino-4-phenyl-1,2,3,4-tetrahydro-2,2,4-trimethylquinoline (II) was prepared in 4 stages. The prepared compds. are FSH (TSH) modulators and, thus, are useful to control fertility. For example, compound II showed excellent in vitro bioactivity (EC50 < 10-7 M) against chinese hamster ovary cells transfected with human FSH receptor.
IT [illegible]

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
[illegible]
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tetrahydroquinoline derivs. and use thereof to control fertility)
RN 328456-17-8 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-(4-methylphenyl)-6-quinolinyl]- (9CI) (CA INDEX NAME)



RN 327901-36-6 CAPLUS
CN Acetamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-(4-methylphenyl)-6-quinolinyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



RN 360760-14-1 CAPLUS
CN Acetamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-2,2,2-trifluoro- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 467064-24-8 CAPLUS
CN Carbamic acid, (1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 467064-29-9 CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-4-chloro- (9CI) (CA INDEX NAME)



RN 467064-30-2 CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 467064-31-3 CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 467064-32-4 CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-4-nitro- (9CI) (CA INDEX NAME)



RN 467064-33-5 CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 467064-34-6 CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-3-bromo-2,6-dimethoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 467064-35-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)



RN 467064-36-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-4'-chloro- (9CI) (CA INDEX NAME)



RN 467064-37-9 CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 467064-38-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-

L6 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
trimethyl-4-phenyl-6-quinolinyl)-4-methoxy- (9CI) (CA INDEX NAME)



AN 467064-79-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[3-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl]-4-methyl- (9CI) (CA INDEX NAME)



AN 467064-61-3 CAPLUS
CN 4-Quinolinamine, 1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-N-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)



AN 467064-61-9 CAPLUS
CN Benzenepropanamide, N-[3-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
AN 467064-49-9 CAPLUS
CN Propanoic acid, 3-[(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



AN 467064-58-8 CAPLUS
CN Propanediamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)-N'-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



AN 467064-53-3 CAPLUS
CN Glycine, N-(1-acetyl-1,2,2,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)-N-oxo- 9-oxiranyl-, ethyl ester (9CI) (CA INDEX NAME)



AN 467064-52-2 CAPLUS
CN Propanediamide, N'-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)-N-ethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AN 467064-68-0 CAPLUS
CN 3-Furancarboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)



AN 467064-67-1 CAPLUS
CN Butanamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)-3-methyl- (9CI) (CA INDEX NAME)



AN 467064-66-2 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-propanamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AN 467064-56-1 CAPLUS
CN Acetamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl]-2-[[2,4-difluorophenyl]methyl]amino]- (9CI) (CA INDEX NAME)

AN 467064-59-4 CAPLUS
CN 1-Piperidineacetamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)-6-phenyl- (9CI) (CA INDEX NAME)



AN 467064-54-9 CAPLUS
CN 4-Morpholineacetamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)



AN 467064-72-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4,8-tetramethyl-6-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AN 467064-73-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-4-methoxy-2,2,4-trimethyl-6-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)



AN 467064-74-5 CAPLUS
CN 2-Furancarboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-(4-methylphenyl)-6-quinolinyl)- (9CI) (CA INDEX NAME)



AN 467064-75-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-(4-methylphenyl)-6-quinolinyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AN 467064-76-7 CAPLUS
CN Propanoic acid, 3-[[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-(4-methylphenyl)-6-quinolinyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



AN 467064-77-7 CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)-3,5-dibromo- (9CI) (CA INDEX NAME)



AN 467064-78-8 CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)-5-bromo-2-(methylamino)- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AN 467064-79-9 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-3,5,6-trimethoxy- (9CI) (CA INDEX NAME)



AN 467064-80-3 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-quinolinyl]-2,6-dimethoxy-3,5-dimethyl- (9CI) (CA INDEX NAME)



AN 467064-81-4 CAPLUS
CN Benzamide, 2-(acetyloxy)-N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AN 467064-82-5 CAPLUS
CN 1,2-Benzenedicarboxamide, N3-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-3-phenyl-6-quinolinyl]-N1,N1-dimethyl- (9CI) (CA INDEX NAME)



AN 467064-84-7 CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



AN 467064-85-8 CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)-2-[(methylsulfonyl)oxy]- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AN 467064-99-5 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-4-(4-hydroxyphenyl)-2,2,4-trimethyl-6-quinolinyl]- (9CI) (CA INDEX NAME)



AN 467065-00-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)-5-methyl- (9CI) (CA INDEX NAME)



AN 467065-04-3 467065-05-4 467065-06-5
467065-07-6 467065-14-5 467065-16-7 467065-19-0 467065-20-3 467065-23-6
RLS: BCT (Biochemical genetics); BSU (Biological study, unclassified); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrahydroquinoline derivs. and use thereof to control fertility)

AN 467065-04-4 CAPLUS

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AN 467065-00-7 CAPLUS
CN Acetamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)-2-bromo- (9CI) (CA INDEX NAME)

AN 467065-08-5 CAPLUS
CN Benzamide, N-[1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl]-2-methoxy- (9CI) (CA INDEX NAME)



AN 467065-19-0 CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)-2-hydroxy- (9CI) (CA INDEX NAME)



AN 467065-20-3 CAPLUS
CN 2-Propenamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-4-phenyl-6-quinolinyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 6 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Benzamide, N-[3-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl]-4-bromo- (9CI) (CA INDEX NAME)

AN 467065-05-4 CAPLUS
CN Benzamide, N-(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)-3-bromo-5-methyl- (9CI) (CA INDEX NAME)

AN 467065-01-0 CAPLUS
CN Propanoic acid, 3-[(1-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)amino]-3-oxo- (9CI) (CA INDEX NAME)

L6 ANSWER 7 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Benzamide, N-[3-acetyl-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl]-4-iodo- (9CI) (CA INDEX NAME)

AN 467065-13-4 CAPLUS
CN Benzamide, N-[3-acetyl-1,2,3,4-tetrahydro-4-[(4-methoxyphenyl)-2,2,4-trimethyl-6-quinolinyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 8 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN [1,1'-Biphenyl]-4-carboxamide, N-[1-acetyl-1,2,3,4-tetrahydro-4-(4-methoxyphenyl)-2,2,4-trimethyl-6-quinolinyl]- (9CI) (CA INDEX NAME)

```
=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 16:56:56 ON 03 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 29, 2007 (20070629/UP).

=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                    1.50      209.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY     SESSION
CA SUBSCRIBER PRICE                                    0.00       -4.68

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 17:11:41 ON 03 JUL 2007

Connecting via Winsock to STN



Welcome to STN International!  Enter x:X

LOGINID:SSPTADK01625

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'STNGUIDE' AT 17:14:59 ON 03 JUL 2007
FILE 'STNGUIDE' ENTERED AT 17:14:59 ON 03 JUL 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> d his

     (FILE 'HOME' ENTERED AT 16:51:11 ON 03 JUL 2007)

     FILE 'REGISTRY' ENTERED AT 16:51:33 ON 03 JUL 2007
L1             STRUCTURE UPLOADED
L2           1 S L1
L3             STRUCTURE UPLOADED
L4           1 S L3
L5         237 S L3 FULL

     FILE 'CAPLUS' ENTERED AT 16:55:47 ON 03 JUL 2007
L6           5 S L5

     FILE 'STNGUIDE' ENTERED AT 16:56:56 ON 03 JUL 2007

=> analyze l5
NO ANSWERS ANALYZED.  THE ANSWER SET WAS CREATED IN FILE 'REGISTRY'.
USE THE FILE COMMAND TO CHANGE TO THE CORRECT FILE.
An answer set can be processed to create terms only
in the same file in which it was created.

=> FIL REGISTRY
```



```
FILE 'REGISTRY' ENTERED AT 17:15:40 ON 03 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     2 JUL 2007  HIGHEST RN 940683-34-1
DICTIONARY FILE UPDATES:    2 JUL 2007  HIGHEST RN 940683-34-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> analyze l5
ENTER ANSWER NUMBER OR RANGE (1-):237
ENTER DISPLAY CODE (CHEM) OR ?:?
Enter one or more codes from the following list.
AF ------ Alternate Molecular Formula
AR ------ Alternate Registry Number
CCI ----- Component Substance Class Identifier
CHEM ---- CAS Registry Numbers and Selected Names
CI ------ Substance Class Identifier
CMF ----- Component Molecular Formulas
CN ------ Chemical Names (Up to 50)
CRN ----- Component Registry Numbers
DEF ----- Definition
DR ------ Deleted Registry Number
EA ------ Elemental Analysis for Ring System
ES ------ Elemental Sequence for Ring System
FCN ----- All Chemical Names
FS ------ File Segment
IN ------ CA Index Name
LC ------ CAS Registry Number Locator
MF ------ Molecular Formula
NAME ---- Selected Substance Names
PCT ----- Polymer Class Term
PR ------ Preferred Registry Number
PN ------ Patent Number
RF ------ Ring System Formula
RID ----- Ring Identifier
RL------- CAplus Super roles
RLD ----- CAplus Super roles for non-specific Derivatives
RL.NP --- Roles from Non-patents
RL.P ---- Roles from Patents
RLD.NP -- Roles for non-specific derivatives from Non-patents
RLD.P --- Roles for non-specific derivatives from Patents
```



```
RLS ----- All CAplus Super roles
RLS.NP -- CAplus Super roles - Non-patents
RLS.P --- CAplus Super roles - Patents
RN ------ CAS Registry Number
RR ------ Replacing Registry Number
SCN ----- Short Chemical Name (IN and OTHER NAMES)
SEQ ----- Protein Sequence Display using 1 Letter Amino Acid Codes (default)
SEQ3 ---- Protein Sequence Display using 3 Letter Amino Acid Codes
SQEPP --- Protein Sequence (exact family search form)
SQEN ---- Nucleic Acid Sequence (exact search form)
SQEP ---- Protein Sequence (exact search form)
SQSPP --- Protein Sequence (subsequence family search form)
SQSN ---- Nucleic Acid Sequence (subsequence search form)
SQSP ---- Protein Sequence (subsequence search form)
SR ------ Source of Registration
SZ ------ Size for Ring System
TAGS ---- Experimental Tags (same as ETAG)
ENTER DISPLAY CODE (CHEM) OR ?:end

=> analyze l5
ENTER ANSWER NUMBER OR RANGE (1-):237
ENTER DISPLAY CODE (CHEM) OR ?:rn
L7           ANALYZE L5 237 RN :        1 TERM

=> analyze l5
ENTER ANSWER NUMBER OR RANGE (1-):1-237
ENTER DISPLAY CODE (CHEM) OR ?:rn
L8           ANALYZE L5 1-237 RN :      237 TERMS

=> file caplus
FILE 'CAPLUS' ENTERED AT 17:19:01 ON 03 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 3 Jul 2007  VOL 147 ISS 2
FILE LAST UPDATED: 2 Jul 2007  (20070702/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> fsh receptor
FSH IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
```



```
"HELP COMMANDS" at an arrow prompt (=>).

=> s fsh receptor
          28554 FSH
         706296 RECEPTOR
         648384 RECEPTORS
         841582 RECEPTOR
                (RECEPTOR OR RECEPTORS)
L9         1529 FSH RECEPTOR
                (FSH(W)RECEPTOR)

=> s l9 and review/dt
        2044284 REVIEW/DT
L10         201 L9 AND REVIEW/DT

=> d scan
```

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-8 (Mammalian Hormones)
TI Synthetic peptides corresponding to segments of the FSH-beta subunit have in vivo biologic effects in male and female mice: A novel and surprising finding
ST review FSH beta subunit gender difference estrus development fertility
IT Estrus
Fertility
Puberty
Sex
(synthetic peptides corresponding to segments of FSH-beta subunit have in vivo biol. effects in male and female mice in relation to novel and surprising findings)
IT FSH receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(synthetic peptides corresponding to segments of FSH-beta subunit have in vivo biol. effects in male and female mice in relation to novel and surprising findings)
IT 9002-68-0D, Follicle-stimulating hormone, β-chain fragments
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(synthetic peptides corresponding to segments of FSH-beta subunit have in vivo biol. effects in male and female mice in relation to novel and surprising findings)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-8 (Mammalian Hormones)
TI Regulation of expression of the FSH receptor
ST review FSH receptor testis ovary
IT Receptors
RL: BIOL (Biological study)
(FSH, expression of, in testis Sertoli cells and ovary granulosa cells,
regulation of)
IT Testis, metabolism
(Sertoli cell, FSH receptors expression in, regulation of)
IT Ovary, metabolism
(follicle cell, FSH receptors expression in, regulation of)
IT 9002-68-0, FSH
RL: BIOL (Biological study)
(receptors for, of testis Sertoli cells and ovary granulosa cells, regulation of)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 14-8 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 2
TI Ovarian hyper-stimulation syndrome due to a mutation in the follicle-stimulating hormone receptor
ST review ovarian hyperstimulation syndrome mutation FSH receptor
IT Ovary, disease
(hyperstimulation syndrome; FSH receptor mutation in)
IT Mutation
(ovarian hyperstimulation syndrome due to mutation in FSH receptor)
IT FSH receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ovarian hyperstimulation syndrome due to mutation of)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 14-8 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 2
TI Molecular pathophysiology and clinical manifestations of gonadotropin receptor defects
ST review LH FSH receptor mutation infertility
IT Amenorrhea
Mutation
(gonadotropin receptor defects and mol. pathophysiol. and clin. manifestations in human)
IT FSH receptors
Gonadotropin receptors
RL: ADV (Adverse effect, including toxicity); BOC (Biological
occurrence);
BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(gonadotropin receptor defects and mol. pathophysiol. and clin. manifestations in human)
IT Fertility
Fertility
(male, disorder; gonadotropin receptor defects and mol. pathophysiol. and clin. manifestations in human)
IT Androgens
RL: ADV (Adverse effect, including toxicity); BOC (Biological
occurrence);
BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(resistance; gonadotropin receptor defects and mol. pathophysiol. and clin. manifestations in human)
IT 9002-67-9, LH 9002-68-0, FSH
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gonadotropin receptor defects and mol. pathophysiol. and clin. manifestations in human)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-8 (Mammalian Hormones)
TI Follicular reserve and response to stimulation. Molecular genetic aspects
ST review FSH receptor polymorphism ovary stimulation IVF
IT Gene, animal
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(FSH receptor; role of FSH receptor gene polymorphism on ovarian response to stimulation therapy and timing of follicular depletion)
IT Ovary
(follicle; role of FSH receptor gene polymorphism on ovarian response to stimulation therapy and timing of follicular depletion)
IT Genetic polymorphism
Human
In vitro fertilization
Ovarian cycle
Ovulation induction
(role of FSH receptor gene polymorphism on ovarian response to stimulation therapy and timing of follicular depletion)
IT FSH receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(role of FSH receptor gene polymorphism on ovarian response to stimulation therapy and timing of follicular depletion)
IT 50-28-2, Estradiol, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(role of FSH receptor gene polymorphism on ovarian response to stimulation therapy and timing of follicular depletion)
IT 9002-68-0, FSH
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(role of FSH receptor gene polymorphism on ovarian response to stimulation therapy and timing of follicular depletion)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 14-8 (Mammalian Pathological Biochemistry)
TI Mutations and polymorphisms in gonadotropin and gonadotropin receptor genes
ST review LH receptor mutation polymorphism male infertility; FSH receptor mutation polymorphism male infertility review
IT Gene, animal
RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)
(FSHb; FSH and receptor gene mutations and polymorphisms in male fertility disorder)
IT Gene, animal
RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)
(FSHR; FSH and receptor gene mutations and polymorphisms in male fertility disorder)
IT Genetic polymorphism
Mutation
(LH and FSH and their receptor gene mutations and polymorphisms in
male
fertility disorder)
IT Gene, animal
RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)
(LHb; LH and receptor gene mutations and polymorphisms in male
fertility
disorder)
IT Gene, animal
RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)
(LHR; LH and receptor gene mutations and polymorphisms in male fertility disorder)
IT Fertility
(male, disorder; LH and FSH and their receptor gene mutations and polymorphisms in male fertility disorder)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-8 (Mammalian Hormones)
TI LH, FSH, and TSH receptors: a new family of protein G-bound receptors
ST review receptor LH FSH TSH; pituitary hormone receptor review
IT G proteins (guanine nucleotide-binding proteins)
RL: BIOL (Biological study)
(FSH and LH and TSH receptors binding by)
IT Receptors
RL: SPN (Synthetic preparation); PREP (Preparation)
(FSH)
IT Receptors
RL: SPN (Synthetic preparation); PREP (Preparation)
(TSH)
IT Receptors
RL: SPN (Synthetic preparation); PREP (Preparation)
(gonadotropin)
IT Gonadotropins
RL: SPN (Synthetic preparation); PREP (Preparation)
(receptors)
IT 9002-67-9, LH 9002-68-0, FSH 9002-71-5, TSH
RL: BIOL (Biological study)
(receptors for)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-8 (Mammalian Hormones)
TI Development of hormonally based male contraceptives - a perspective
ST review male contraceptive vaccine FSH LH Norethisterone estradiol GnRH
IT Vaccines
(contraceptive; perspective for hormone-based male contraceptives)
IT Contraceptives
(male; perspective for hormone-based male contraceptives)
IT Fertilization
Human
Spermatogenesis
(perspective for hormone-based male contraceptives)
IT FSH receptors
Gonadotropin receptors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(perspective for hormone-based male contraceptives)
IT Contraceptives
(vaccines; perspective for hormone-based male contraceptives)
IT 50-28-2, Estradiol, biological studies 68-22-4, Norethisterone 9002-67-9, LH 9002-68-0, FSH 9034-40-6, GnRH
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(perspective for hormone-based male contraceptives)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-8 (Mammalian Hormones)
TI Gonadotropin receptor mutations
ST review gonadotropin receptor FSH gene mutation
IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(FSH receptor; gonadotropin receptor mutations effect on phenotypes in humans)
IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(LH receptor; gonadotropin receptor mutations effect on phenotypes in humans)
IT Mutation
Phenotypes
Sex
(gonadotropin receptor mutations effect on phenotypes in humans)
IT FSH receptors
Gonadotropin receptors
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(gonadotropin receptor mutations effect on phenotypes in humans)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-8 (Mammalian Hormones)
Section cross-reference(s): 3, 14
TI An update of the pathophysiology of human gonadotrophin subunit and receptor gene mutations and polymorphisms
ST review pathophysiol gonadotropin subunit receptor gene mutation polymorphism
IT Pituitary hormones
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gonadotropins, α subunit; pathophysiol. of human gonadotropin subunit and receptor gene mutations and polymorphisms)
IT Genetic polymorphism
Human
Mutation
Structure-activity relationship
(pathophysiol. of human gonadotropin subunit and receptor gene mutations and polymorphisms)
IT Gene, animal
Gonadotropins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pathophysiol. of human gonadotropin subunit and receptor gene mutations and polymorphisms)
IT FSH receptors
Gonadotropin receptors
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(pathophysiol. of human gonadotropin subunit and receptor gene mutations and polymorphisms)
IT 9002-67-9, LH 9002-68-0, FSH
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pathophysiol. of human gonadotropin subunit and receptor gene mutations and polymorphisms)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 14-8 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 2, 3
TI Follicle-stimulating hormone ligand and receptor mutations, and gonadal dysfunction
ST review FSH receptor gene mutation infertility
IT Genetic polymorphism
Mutation
Ovary
Sex
(FSH ligand and receptor mutations and gonadal dysfunction in humans)
IT FSH receptors
RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)
(FSH ligand and receptor mutations and gonadal dysfunction in humans)
IT G proteins (guanine nucleotide-binding proteins)
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(FSH ligand and receptor mutations and gonadal dysfunction in humans)
IT Gene, animal
RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)
(FSHb; FSH ligand and receptor mutations and gonadal dysfunction in humans)
IT Fertility
(female, disorder; FSH ligand and receptor mutations and gonadal dysfunction in humans)
IT Fertility
(male, disorder; FSH ligand and receptor mutations and gonadal dysfunction in humans)
IT 9002-68-0, Follicle-stimulating hormone
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); BIOL (Biological study)
(FSH ligand and receptor mutations and gonadal dysfunction in humans)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-8 (Hormone Pharmacology)
TI Regulation and biological properties of receptors for LH, FSH, prolactin, beta-adrenergic amines, and gonadotropin releasing hormone in the luteinized rat ovary
ST review hormone receptor ovary; prolactin receptor ovary review; LHRH receptor ovary review; FSH receptor ovary review; adrenergic receptor ovary review
IT Receptors
RL: BIOL (Biological study)
(for hormones, of ovary)
IT Ovary
(hormone receptors of)
IT Sympathomimetics
(β-, receptor for, of ovary)
IT 9002-62-4, biological studies 9002-67-9 9002-68-0 9034-40-6
RL: BIOL (Biological study)
(receptor for, of ovary)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-8 (Mammalian Hormones)
TI Functional correlates of the growth factor structure of pituitary follitropin
ST review FSH structure biol function relationship
IT Signal transduction, biological
Structure-activity relationship
(functional correlates of growth factor structure of pituitary follitropin and related signalling)
IT 9002-68-0, FSH
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(functional correlates of growth factor structure of pituitary follitropin and related signalling)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-8 (Mammalian Hormones)
TI The molecular biology of the FSH receptor
ST review FSH receptor mol biol; gene FSH receptor review
IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(FSH receptor mol. biol.)
IT Receptors
RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
BPN
(Biosynthetic formation); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence)
(FSH, FSH receptor mol. biol.)
IT 9002-68-0, FSH
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FSH receptor mol. biol.)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 1-8 (Pharmacology)
Section cross-reference(s): 2
TI Does hormone replacement therapy prevent epithelial ovarian cancer?
ST review hormone replacement therapy epithelial ovarian cancer
IT Hormone replacement therapy
Human
(FSH receptor and LH receptor was present in ovarian surface epithelium and in malignant epithelial ovarian tissue while hormone replacement therapy can lower gonadotropins FSH and LH but not hCG concentration in human)
IT FSH receptors
Gonadotropin receptors
Gonadotropins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FSH receptor and LH receptor was present in ovarian surface epithelium and in malignant epithelial ovarian tissue while hormone replacement therapy can lower gonadotropins FSH and LH but not hCG concentration in human)
IT Ovary, neoplasm
(carcinoma; FSH receptor and LH receptor was present in ovarian surface epithelium and in malignant epithelial ovarian tissue while hormone replacement therapy can lower gonadotropins FSH and LH but not hCG concentration in human)
IT Carcinoma
(ovarian; FSH receptor and LH receptor was present in ovarian surface epithelium and in malignant epithelial ovarian tissue while hormone replacement therapy can lower gonadotropins FSH and LH but not hCG concentration in human)
IT 9002-67-9, Luteinizing hormone 9002-68-0, Follicle-stimulating hormone
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FSH receptor and LH receptor was present in ovarian surface epithelium and in malignant epithelial ovarian tissue while hormone replacement therapy can lower gonadotropins FSH and LH but not hCG concentration in human)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 14-8 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 2, 3
TI FSH resistance
ST review FSH resistance
IT Mutation
(in FSH and FSH receptor genes in FSH resistance)
IT FSH receptors
Gene, animal
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(mutations in FSH and FSH receptor genes in FSH resistance)
IT 9002-68-0, FSH
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(resistance; FSH resistance)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 14-0 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 3
TI Candidate genes for premature ovarian failure
ST review genetics premature ovary failure
IT Genetics
Human
(altered genetics of)
IT Ovary, disease
(failure; altered genetics of)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 14-0 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 3
TI The inhibins and ovarian cancer
ST review inhibin ovarian cancer
IT Ovary, neoplasm
Tumor markers
(inhibins and ovarian cancer in humans)
IT Diagnosis
(mol.; inhibins and ovarian cancer in humans)
IT 57285-09-3, Inhibin
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(inhibins and ovarian cancer in humans)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 14-0 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 2
TI Endocrine regulation of testicular function in infertile men
ST review FSH testis function infertility
IT Testis
(function of, in infertile men, FSH in relation to)
IT Fertility
(male, disorder, testis function in men in, FSH in relation to)
IT 9002-68-0, FSH
RL: BSU (Biological study)
(testis function in infertile men in relation to)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 14-0 (Mammalian Pathological Biochemistry)
TI New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome?
ST review FSH receptor vasoactive protein ovary hyperstimulation syndrome
IT FSH receptors
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(FSHR association with spontaneous and iatrogenic ovarian
hyperstimulation
syndrome)
IT Ovary, disease
(hyperstimulation syndrome; pathophysiol. of spontaneous and
iatrogenic
ovarian hyperstimulation syndrome)
IT Human
(pathophysiol. of spontaneous and iatrogenic ovarian hyperstimulation syndrome)
IT Hormones, animal, biological studies
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(vasoactive; vasoactive proteins association with spontaneous and iatrogenic ovarian hyperstimulation syndrome)
IT 9002-68-0, FSH
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(FSHR association with spontaneous and iatrogenic ovarian
hyperstimulation
syndrome)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-0 (Mammalian Hormones)
TI Mammalian follicle-stimulating hormone receptors and their ligands
ST review FSH receptor ligand
IT Molecular structure
Signal transduction, biological
(FSH receptors and their ligands)
IT FSH receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(FSH receptors and their ligands)
IT 9002-68-0, FSH
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(FSH receptors and their ligands)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-0 (Mammalian Hormones)
TI FSH and folliculogenesis: from physiology to ovarian stimulation
ST review FSH ovary stimulation follicle folliculogenesis
IT Ovary
(follicle; physiol. of FSH and folliculogenesis in ovarian
stimulation)
IT Ovary, disease
(hyperstimulation syndrome; protocols with softer ovarian stimulation using recombinant FSH are now used to avoid ovarian hyperstimulation syndrome during assisted reproduction in human)
IT Pregnancy
(protocols with softer ovarian stimulation using recombinant FSH are now used to avoid multiple pregnancies during assisted reproduction in human)
IT Human
Ovary
Reproduction, animal
(recombinant FSH along with gonadotropin-releasing hormone agonist or antagonist and LH is used for ovarian stimulation during assisted reproduction in human)
IT 9002-67-9, Luteinizing hormone 9002-68-0, Follicle-stimulating hormone 9034-40-6, Gonadotropin-releasing hormone
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(recombinant FSH along with gonadotropin-releasing hormone agonist or antagonist and LH is used for ovarian stimulation during assisted reproduction in human)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 14-0 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 2
TI Gonadotropin ligand and receptor mutations in disorders of pituitary-gonadal function
ST review gonadotropin receptor gene mutation infertility
IT Amenorrhea
Mutation
Sex
Spermatogenesis
(LH, FSH and their receptors genes mutations in human in disorders of pituitary-gonadal function)
IT FSH receptors
Gonadotropin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LH, FSH and their receptors genes mutations in human in disorders of pituitary-gonadal function)
IT Testis
(Leydig cell, disease, hypoplasia; LH, FSH and their receptors genes mutations in human in disorders of pituitary-gonadal function)
IT Ovulation
(anovulation; LH, FSH and their receptors genes mutations in human in disorders of pituitary-gonadal function)
IT Testis, disease
(azoospermia; LH, FSH and their receptors genes mutations in human in disorders of pituitary-gonadal function)
IT Development, mammalian postnatal
(disorder, sexual; LH, FSH and their receptors genes mutations in
human
in disorders of pituitary-gonadal function)
IT Fertility
(female, disorder; LH, FSH and their receptors genes mutations in
human
in disorders of pituitary-gonadal function)
IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BOC (Biological
occurrence);
BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(gonadotropin subunits; LH, FSH and their receptors genes mutations in human in disorders of pituitary-gonadal function)
IT Hermaphroditism
(male pseudohermaphroditism; LH, FSH and their receptors genes mutations in human in disorders of pituitary-gonadal function)
IT Puberty
(male, disorder, precocious; LH, FSH and their receptors genes mutations in human in disorders of pituitary-gonadal function)
IT Fertility
(male, disorder; LH, FSH and their receptors genes mutations in human in disorders of pituitary-gonadal function)
IT Testis, disease
(oligospermia; LH, FSH and their receptors genes mutations in human in disorders of pituitary-gonadal function)
IT 9002-67-9, LH 9002-68-0, FSH
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LH, FSH and their receptors genes mutations in human in disorders of pituitary-gonadal function)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 6-0 (General Biochemistry)
Section cross-reference(s): 2, 7
TI Photoaffinity labeling of the follitropin receptor
ST follitropin receptor structure review; FSH receptor photoaffinity labeling review
IT Receptors
RL: BIOL (Biological study)
(for FSH, structure of, photoaffinity labeling for studies of)
IT Affinity
(photo-, labeling by, of FSH receptors, for structure studies)
IT 9002-68-0, Follitropin
RL: BIOL (Biological study)
(receptors for, structure of, photoaffinity labeling for studies of)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 14-0 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 1
TI Genetic disorders in premature ovarian failure
ST review genetics disease premature ovary failure
IT Genetics
Human
(altered genetics and genetic disorders associated with premature
ovarian
failure)
IT Ovary, disease
(failure, premature; altered genetics and genetic disorders associated with premature ovarian failure)
IT Disease, animal
(genetic; altered genetics and genetic disorders associated with
premature
ovarian failure)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 14-0 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 2, 3
TI Functional and clinical consequences of mutations in the FSH receptor
ST review FSH receptor mutation activating inactivating
IT Fertility
(female, disorder; functional and clin. consequences of inactivating and activating mutations in human FSH receptor)
IT Fertility
(female, female fertility disorders; functional and clin. consequences of inactivating and activating mutations in human FSH receptor)
IT Mutation
(functional and clin. consequences of inactivating and activating mutations in human FSH receptor)
IT FSH receptors
Gene, animal
RL: ADV (Adverse effect, including toxicity); BOC (Biological
occurrence);
BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(functional and clin. consequences of inactivating and activating mutations in human FSH receptor)
IT Fertility
(male; functional and clin. consequences of inactivating and
activating
mutations in human FSH receptor)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 14-0 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 3, 3
TI Application of ART on genetic disorders causing infertility: Is it safe?
ST review infertility gene mutation X Y chromosome
IT Fertility disorders
Human
Mutation
(genetic disorders causing infertility)
IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(genetic disorders causing infertility)
IT Chromosome
(human X; genetic disorders causing infertility)
IT Chromosome
(human Y; genetic disorders causing infertility)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-0 (Mammalian Hormones)
TI Gonadotropin receptors
ST review gonadotropin receptor
IT FSH receptors
Gonadotropin receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(gonadotropin receptors)
IT 9002-67-9, LH 9002-68-0, FSH
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gonadotropin receptors)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-4 (Hormone Pharmacology)
TI Mechanisms modulating gonadotropin action
ST review gonadotropin action mechanism protein kinase gonadotropin review; FSH receptor ovary review
IT Ovary
(FSH receptors of)
IT Receptors
RL: BIOL (Biological study)
(for FSH, of ovary)
IT Gonadotropins
RL: PRP (Properties)
(mechanism of)
IT 9026-43-1
RL: BIOL (Biological study)
(cyclic AMP-dependent, gonadotropin mechanism in relation to)
IT 9002-68-0
RL: BIOL (Biological study)
(receptors for, of ovary)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 14-0 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 2
TI The ovarian gonadotropin receptors in health and disease
ST review ovarian gonadotropin receptor health disease
IT Reproduction, animal
(female; ovarian gonadotropin receptors in health and disease)
IT Disease models
Human
Mutation
Ovary
(ovarian gonadotropin receptors in health and disease)
IT FSH receptors
Gonadotropin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ovarian gonadotropin receptors in health and disease)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 13-0 (Mammalian Biochemistry)
TI Activation mechanism of early stage oocyte. Evidence from mutant mice
ST review oogenesis oocyte activation biochem
IT Oogenesis
(biochem. of activation of early stage mammalian oocytes)
IT Egg
(oocyte, biochem. of activation of early stage mammalian oocytes)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-0 (Mammalian Hormones)
TI Molecular biology and physiological role of the oocyte factor, BMP-15
ST review oocyte factor BMP15 mol biol physiol
IT Reproduction, animal
(fecundity; mol. biol. and physiol. of oocyte factor BMP-15)
IT Fertility
(female; mol. biol. and physiol. of oocyte factor BMP-15)
IT Ovary
(follicle, folliculogenesis; mol. biol. and physiol. of oocyte factor BMP-15)
IT Human
Mutation
Ovulation
Species differences
(mol. biol. and physiol. of oocyte factor BMP-15)
IT Bone morphogenetic protein 15
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mol. biol. and physiol. of oocyte factor BMP-15)
IT Egg
(oocyte; mol. biol. and physiol. of oocyte factor BMP-15)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10540336.trn

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 1-0 (Pharmacology)
TI Preliminary evaluation of the follitropin receptor structural diversity, mutations, gene knock out and biological implications
ST review fsh receptor follitropin receptor
IT FSH receptors
    RL: BPR (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
      (follitropin receptor snl. genetics and structural diversity and mutations and gene knock out and biol. implications)
IT Genetics
      (snl.; follitropin receptor snl. genetics and structural diversity and mutations and gene knock out and biol. implications)

ENTER HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-0 (Mammalian Hormones)
TI The role of follitropin receptor diversity: A recipe for flow cytometry gonadal responses?
ST review follitropin receptor diversity ovary testis
IT Human
    Ovary
    Testis
      (follitropin receptor diversity and regulation of gonadal function)
IT FSH receptors
    RL: BPR (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
      (follitropin receptor diversity and regulation of gonadal function)

ENTER HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 3-5 (Mammalian Hormones)
TI Molecular genetics of the follitropin receptor: structural diversity, mutations, gene knock out and biological implications
ST review snl genetics follitropin receptor
IT FSH receptors
    RL: BPR (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
      (follitropin receptor snl. genetics and structural diversity and mutations and gene knock out and biol. implications)
IT Genetics
      (snl.; follitropin receptor snl. genetics and structural diversity and mutations and gene knock out and biol. implications)

ENTER HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 3-0 (Mammalian Hormones)
TI Structure and function of gonadotropin. Focusing on β-subunit. 1)
ST review gonadotropin beta subunit structure function
IT Conformation
      (protein; structure and function of gonadotropin β-subunit)
IT Protein sequence
    Structure-activity relationship
      (structure and function of gonadotropin β-subunit)
IT 9002-63-7, LH 9002-64-8, FSH
    RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
      (structure and function of gonadotropin β-subunit)

ENTER HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-0 (Mammalian Hormones)
TI Expression of the FSH receptor in the testis
ST review FSH receptor testis
IT Testis, composition
      (FSH receptors in)
IT Receptors
    RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
      (FSH, of testis)
IT 9002-64-8, FSH
    RL: BIOL (Biological study)
      (receptor (or, in testis)

ENTER HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 1-0 (Pharmacology)
TI Hormone replacement therapy prevent epithelial ovarian cancer?
ST review hormone replacement therapy epithelial ovarian cancer
IT Hormone replacement therapy
    Human
      (FSH receptor and LH receptor was present in ovarian surface epithelium and in malignant epithelial ovarian tissue while hormone replacement therapy can lower gonadotropins FSH and LH but not EOC concentration in human)
IT FSH receptors
    Gonadotropin receptors
    Gonadotropins
    RL: BSU (Biological study, unclassified); BIOL (Biological study)
      (FSH receptor and LH receptor was present in ovarian surface epithelium and in malignant epithelial ovarian tissue while hormone replacement therapy can lower gonadotropins FSH and LH but not EOC concentration in human)
IT Ovary, neoplasm
      (carcinoma; FSH receptor and LH receptor was present in ovarian surface epithelium and in malignant epithelial ovarian tissue while hormone replacement therapy can lower gonadotropins FSH and LH but not EOC concentration in human)
IT Carcinoma
      (ovarian; FSH receptor and LH receptor was present in ovarian surface epithelium and in malignant epithelial ovarian tissue while hormone replacement therapy can lower gonadotropins FSH and LH but not EOC concentration in human)
IT 9001-67-9, Estradiol hormone 9001-69-6, Follicle-stimulating hormone
    RL: BSU (Biological study, unclassified); BIOL (Biological study)
      (FSH receptor and LH receptor was present in ovarian surface epithelium and in malignant epithelial ovarian tissue while hormone replacement therapy can lower gonadotropins FSH and LH but not EOC concentration in human)

ALL ANSWERS HAVE BEEN SCANNED

10540336.trn

=> d his

     (FILE 'HOME' ENTERED AT 16:51:11 ON 03 JUL 2007)

     FILE 'REGISTRY' ENTERED AT 16:51:33 ON 03 JUL 2007
L1   STRUCTURE UPLOADED
L2   1 S L1
L3   STRUCTURE UPLOADED
L4   1 S L3
L5   237 S L3 FULL

     FILE 'CAPLUS' ENTERED AT 16:55:47 ON 03 JUL 2007
L6   5 S L5

     FILE 'STNGUIDE' ENTERED AT 16:56:56 ON 03 JUL 2007

     FILE 'REGISTRY' ENTERED AT 17:15:40 ON 03 JUL 2007
L7   ANALYZE L5 237 RN :   1 TERM
L8   ANALYZE L5 1-237 RN :   237 TERMS

     FILE 'CAPLUS' ENTERED AT 17:19:01 ON 03 JUL 2007
L9   1529 S FSH RECEPTOR
L10   201 S L9 AND REVIEW/DT

=> s l10 and 1-0/cc
        153150 1-0/CC
L11   1 L10 AND 1-0/CC

=> d scan

10540336.trn

=> d scan l10

10540336.trn

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 14-0 (Mammalian Pathological Biochemistry)
TI Understanding ovarian hyperstimulation syndrome
ST review ovary hyperstimulation capillary permeability FSH receptor
IT FSH receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FSH receptor and increased sensitivity to hCG in ovarian hyperstimulation syndrome)
IT Ovary
(follicle; FSH receptor and increased sensitivity to hCG in ovarian hyperstimulation syndrome)
IT Capillary vessel
(permeability; FSH receptor and increased sensitivity to hCG in ovarian hyperstimulation syndrome)
IT Biological transport
(permeation, vascular, capillary; FSH receptor and increased sensitivity to hCG in ovarian hyperstimulation syndrome)
IT Biological transport
(permeation; FSH receptor and increased sensitivity to hCG in ovarian hyperstimulation syndrome)
IT 9002-61-3, Chorionic gonadotropin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FSH receptor and increased sensitivity to hCG in ovarian hyperstimulation syndrome)

ECH WANT MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L19 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-0 (Mammalian Hormones)
TI Gonadotropin actions on the testis - genotype and phenotype of gonadotropin and gonadotropin receptor mutations
ST review gonadotropin receptor testis
IT Testis
(gonadotropin actions on testis in relation to genotype and phenotype of gonadotropin and gonadotropin receptor mutations)
IT FSH receptors
Gonadotropin receptors
Gonadotropins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gonadotropin actions on testis in relation to genotype and phenotype of gonadotropin and gonadotropin receptor mutations)
IT 9002-67-9, LH 9002-66-8, FSH
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gonadotropin actions on testis in relation to genotype and phenotype of gonadotropin and gonadotropin receptor mutations)

ECH WANT MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L19 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 14-0 (Mammalian Pathological Biochemistry)
TI Understanding ovarian hyperstimulation syndrome
ST review ovary hyperstimulation capillary permeability FSH receptor
IT FSH receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FSH receptor and increased sensitivity to hCG in ovarian hyperstimulation syndrome)
IT Ovary
(follicle; FSH receptor and increased sensitivity to hCG in ovarian hyperstimulation syndrome)
IT Capillary vessel
(permeability; FSH receptor and increased sensitivity to hCG in ovarian hyperstimulation syndrome)
IT Biological transport
(permeation; FSH receptor and increased sensitivity to hCG in ovarian hyperstimulation syndrome)
IT 9002-61-3, Chorionic gonadotropin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FSH receptor and increased sensitivity to hCG in ovarian hyperstimulation syndrome)

ECH WANT MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L19 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-0 (Mammalian Hormones)
TI Gonadotropin actions on the testis - genotype and phenotype of gonadotropin and gonadotropin receptor mutations
ST review gonadotropin receptor testis
IT Testis
(gonadotropin actions on testis in relation to genotype and phenotype of gonadotropin and gonadotropin receptor mutations)
IT FSH receptors
Gonadotropin receptors
Gonadotropins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gonadotropin actions on testis in relation to genotype and phenotype of gonadotropin and gonadotropin receptor mutations)
IT 9002-67-9, LH 9002-66-8, FSH
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gonadotropin actions on testis in relation to genotype and phenotype of gonadotropin and gonadotropin receptor mutations)

ECH WANT MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L19 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 14-0 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 2
TI Pathophysiology of the gonadotropic control of gametogenesis
ST review oogenesis ovary gonadotropin assay
IT Fertility
(disorder, female; gonadotropins and gametogenesis pathophysiol. in human and laboratory animal)
IT Ovary
(follicle; gonadotropins and gametogenesis pathophysiol. in human and laboratory animal)
IT Follicle
Mutation
Ovulation
Spermatogenesis
(gonadotropins and gametogenesis pathophysiol. in human and laboratory animal)
IT FSH receptors
Gonadotropin receptors
Gonadotropin-releasing hormone receptor
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PAC (Pharmacological activity); PEP (Physiological process); RCT (Reactant); RGT (Reagent); TEST (Testing event); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(gonadotropins and gametogenesis pathophysiol. in human and laboratory animal)
IT Reproductive tract
(hypogonadism; gonadotropins and gametogenesis pathophysiol. in human and laboratory animal)
IT Fertility
(male, disorder; gonadotropins and gametogenesis pathophysiol. in human and laboratory animal)
IT Development, mammalian prenatal
(sexual differentiation; gonadotropins and gametogenesis pathophysiol. in human and laboratory animal)
IT 9002-67-9, LH 9002-66-8, FSH 9041-08-0, GnRH
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physiological process); RCT (Reactant); RGT (Reagent); TEST (Testing event); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(gonadotropins and gametogenesis pathophysiol. in human and laboratory animal)

ECH WANT MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10540336.trn

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-0 (Mammalian Hormones)
TI Gonadotropin control of oocyte maturation
ST review gonadotropin oogenesis
IT Meiosis
Oogenesis
(gonadotropin control of oocyte maturation)
IT Gonadotropins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(gonadotropin control of oocyte maturation)
IT Egg
(oocyte; gonadotropin control of oocyte maturation)
IT 9002-67-9, LH 9002-66-8, FSH
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(gonadotropin control of oocyte maturation)

ECH WANT MORE ANSWERS DO YOU WISH TO SCAN? 11:1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 14-0 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 2
TI Pathophysiology of the gonadotropic control of gametogenesis
ST review oogenesis ovary gonadotropin assay
IT Fertility
(disorder, female; gonadotropins and gametogenesis pathophysiol. in human and laboratory animal)
IT Ovary
(follicle; gonadotropins and gametogenesis pathophysiol. in human and laboratory animal)
IT Follicle
Mutation
Ovulation
Spermatogenesis
(gonadotropins and gametogenesis pathophysiol. in human and laboratory animal)
IT FSH receptors
Gonadotropin receptors
Gonadotropin-releasing hormone receptor
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PAC (Pharmacological activity); PEP (Physiological process); RCT (Reactant); RGT (Reagent); TEST (Testing event); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(gonadotropins and gametogenesis pathophysiol. in human and laboratory animal)
IT Reproductive tract
(hypogonadism; gonadotropins and gametogenesis pathophysiol. in human and laboratory animal)
IT Fertility
(male, disorder; gonadotropins and gametogenesis pathophysiol. in human and laboratory animal)
IT Development, mammalian prenatal
(sexual differentiation; gonadotropins and gametogenesis pathophysiol. in human and laboratory animal)
IT 9002-67-9, LH 9002-66-8, FSH 9041-08-0, GnRH
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physiological process); RCT (Reactant); RGT (Reagent); TEST (Testing event); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(gonadotropins and gametogenesis pathophysiol. in human and laboratory animal)

ECH WANT MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10540336.trn

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-0 (Mammalian Hormones)
TI Gonadotropin control of ovarian development
ST review gonadotropin ovary development
IT Cell differentiation
Cell proliferation
Ovary
Ovulation
(Gonadotropin; control of ovarian development)
IT Gonadotropin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gonadotropin control of ovarian development)

ECH WANT MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10540336.trn

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 14-0 (Mammalian Pathological Biochemistry)
TI Candidate genes for premature ovarian failure
ST review genetics premature ovary failure
IT Genetics
Human
(altered genetics of)
IT Ovary, disease
(failure; altered genetics of)

ECH WANT MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 201 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 2-0 (Mammalian Hormones)
Section cross-reference(s): 9
TI Ovarian transcriptomes as a tool for a global approach of genes modulated by gonadotropin hormones in human ovarian granulosa cells
ST review ovary transcriptome gonadotropin ovulation corpus luteum desensitization; DNA microarray technol gonadotropin ovary review
IT Corpus luteum
(desensitization of; ovarian transcriptomes as tool for global approach of genes modulated by gonadotropic hormones in human ovarian granulosa cells)
IT Ovary
(follicle cell; ovarian transcriptomes as tool for global approach of genes modulated by gonadotropic hormones in human ovarian granulosa cells)
IT DNA microarray technology
Gene expression profiles, animal
Human
Ovulation
Signal transduction, biological
(ovarian transcriptomes as tool for global approach of genes modulated by gonadotropic hormones in human ovarian granulosa cells)
IT FSH receptors
Gonadotropin receptors
Gonadotropins
Transcriptome
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ovarian transcriptomes as tool for global approach of genes modulated by gonadotropic hormones in human ovarian granulosa cells)
IT 9002-67-9, LH 9001-66-6, FSH 117147-78-3, Amphiregulin 196717-71-3, Epiregulin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ovarian transcriptomes as tool for global approach of genes modulated by gonadotropic hormones in human ovarian granulosa cells)

ECH WANT MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10540336.trn

=> d his

(FILE 'HOME' ENTERED AT 16:51:11 ON 03 JUL 2007)

FILE 'REGISTRY' ENTERED AT 16:51:33 ON 03 JUL 2007
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 STRUCTURE UPLOADED
L4 1 S L3
L5 237 S L3 FULL

FILE 'CAPLUS' ENTERED AT 16:55:47 ON 03 JUL 2007
L6 5 S L5

FILE 'STNGUIDE' ENTERED AT 16:56:56 ON 03 JUL 2007

FILE 'REGISTRY' ENTERED AT 17:15:40 ON 03 JUL 2007
L7 ANALYZE L5 237 RN : 1 TERM
L8 ANALYZE L5 1-237 RN : 237 TERMS

FILE 'CAPLUS' ENTERED AT 17:19:01 ON 03 JUL 2007
L9 1529 S FSH RECEPTOR
L10 201 S L9 AND REVIEW/DT
L11 1 S L10 AND 1-0/CC

=> s l10 and antagonist
170147 ANTAGONIST
125603 ANTAGONISTS
230224 ANTAGONIST
(ANTAGONIST OR ANTAGONISTS)
L12 6 L10 AND ANTAGONIST

=> d scan

10540336.trn

L11 1 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 1-0 (Mammalian Hormones)
TI Role of FSH in male gonadal function
ST review FSH testis function
IT Spermatogenesis
Testis
(role of FSH in male gonadal function)
IT 9002-68-0, FSH
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
process); BUU (Biological study, unclassified); BIOL (Biological study);
PHAC (Pharmacological activity)
(role of FSH in male gonadal function)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 1 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 1-0 (Mammalian Hormones)
TI FSH and folliculogenesis: Iron physiology to ovarian stimulation
ST review FSH ovary stimulation follicle folliculogenesis
IT Ovary
(follicle; physiol. of FSH and folliculogenesis in ovarian
stimulation)
IT Ovary, disease
(hyperstimulation syndrome; protocols with refter ovarian stimulation
using recombinant FSH are now used to avoid ovarian hyperstimulation
syndrome during assisted reproduction in human)
IT Pregnancy
(protocols with refter ovarian stimulation using recombinant FSH are
now used to avoid multiple pregnancies during assisted reproduction in
human)
IT Human
Ovary
Reproduction, animal
(recombinant FSH along with gonadotropin-releasing hormone agonist or
antagonist and LH is used for ovarian stimulation during
assisted reproduction in human)
IT 9002-67-9, Luteinizing hormone 9002-68-0, Follicle-stimulating hormone
9034-68-6, Gonadotropin-releasing hormone
RL: BUU (Biological study, unclassified); BIOL (Biological study)
(recombinant FSH along with gonadotropin-releasing hormone agonist or
antagonist and LH is used for ovarian stimulation during
assisted reproduction in human)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 6 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 1-0 (Mammalian Hormones)
TI Small molecule agonists and antagonists for the LH and
FSH receptors
ST review FSH receptor agonist antagonist
fertility agent contraceptive; LH receptor agonist antagonist
fertility agent contraception review
IT Fertility
(agents; small mol. agonists and antagonists for LH and
FSH receptors and use in fertility control)
IT FSH receptors
Gonadotropin receptors
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(agonists and antagonists; small mol. agonists and
antagonists for LH and FSH receptors and
use in fertility control)
IT Contraceptives
Fertility disorders
Human
(small mol. agonists and antagonists for LH and FSH
receptors and use in fertility control)
IT 9002-67-9, Luteinizing hormone 9002-69-0, FTH
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(small mol. agonists and antagonists for LH and FSH
receptors and use in fertility control)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 6 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 1-0 (Mammalian Hormones)
TI Overriding follicle selection in controlled ovarian stimulation
protocols
Quality vs. quantity
ST review follicle retrieval assisted reprodn primate
IT Reproduction, animal
(assisted; overriding follicle selection in controlled ovarian
stimulation protocols)
IT Ovary
(follicle; overriding follicle selection in controlled ovarian
stimulation protocols)
IT Egg
(oocyte; overriding follicle selection in controlled ovarian
stimulation protocols)
IT Cynomolgus primate
(overriding follicle selection in controlled ovarian stimulation
protocols)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10540336.trn

L11 6 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 1-0 (Mammalian Hormones)
TI Role of FSH in male gonadal function
ST review FSH testis function
IT Spermatogenesis
Testis
(role of FSH in male gonadal function)
IT 9002-68-0, FSH
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological process); BUU (Biological study, unclassified); BIOL (Biological study);
PHAC (Pharmacological activity)
(role of FSH in male gonadal function)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 6 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 1-0 (Mammalian Hormones)
TI Development of hormonally based male contraceptives - a perspective
ST review male contraceptive vaccine FSH LH Gerithidorma estradiol GnRH
IT Vaccines
Immunogens
(immunogens; perspective for hormone-based male contraceptives)
IT Contraceptives
(male; perspective for hormone-based male contraceptives)
IT Fertilization
Human
Spermatogenesis
(perspective for hormone-based male contraceptives)
IT FSH receptors
Gonadotropin receptors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(perspective for hormone-based male contraceptives)
IT Contraceptives
(vaccines; perspective for hormone-based male contraceptives)
IT 58-19-5, Estradiol, biological studies 60-27-5, Gerithidorma
9002-67-9, LH 9002-68-0, FSH 9034-68-6, GnRH
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(immunogens; perspective for hormone-based male contraceptives)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L11 6 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
CC 1-0 (Mammalian Hormones)
TI Ovarian follicle development: the role of oocyte GDF-9 and GDF-9B/BMP-15
ST review ovarian follicle development oocyte GDF9 BMP15 growth
differentiation factor bone morphogenic protein ovarian follicle review
IT Bone morphogenetic proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(BMP-15; the role of oocyte GDF-9 and GDF-9B/BMP-15 in ovarian
follicle
development, ovulation and fecundity)
IT Reproduction, animal
(fecundity; the role of oocyte GDF-9 and GDF-9B/BMP-15 in ovarian
follicle development, ovulation and fecundity)
IT Ovary
(follicle; the role of oocyte GDF-9 and GDF-9B/BMP-15 in ovarian
follicle development, ovulation and fecundity)
IT Egg
(oocyte; the role of oocyte GDF-9 and GDF-9B/BMP-15 in ovarian
follicle
development, ovulation and fecundity)
IT Fertility disorders
Human
Ovulation
(the role of oocyte GDF-9 and GDF-9B/BMP-15 in ovarian follicle
development, ovulation and fecundity)
IT 204779-84-1, GDF-9
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(the role of oocyte GDF-9 and GDF-9B/BMP-15 in ovarian follicle
development, ovulation and fecundity)

ALL ANSWERS HAVE BEEN SCANNED

10540336.trn

=> d cbib abs 1-6

10540336.trn

L12 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
2006:631193 Document No. 145:209217 FSH and follitropinoids: from physiology to ovarian stimulation. Hugues, Walter; Alagna, Federica [Infertility Unit, Ginecopatil e Hagina Elena, Fondazione I.R.C.C.S. Ospedale Maggiore Policlinico, Milan, Italy]. Reproductive Biomedicine Online, 12(6), 666-674 (English) 2006. CODEN: RBOAB6. ISSN: 1472-6483. Publisher: Reproductive Healthcare Ltd..
AB A review. FSH is a glycoprotein hormone consisting of two peptide subunits. The role of rFSH in follitropinoids is well known to stimulate the formation of a large pre-ovulatory follicle that, because of its FSH-dependent cultivation, is capable of ovulation and forming a corpus luteum in response to the mid-cycle surge of LH. FSH is widely used to ovarian stimulation for assisted reproduction techniques. Ovarian stimulation protocols combine the use of human menopausal gonadotrophin, urinary FSH or recombinant FSH with gonadotrophin-releasing hormone (GnRH) agonists or antagonists in order to increase oocyte number and to avoid premature LH surges. Recently, the availability of recombinant LH has permitted new stimulation protocols, combining recombinant FSH, recombinant LH and GnRH antagonists. Due to the limitations of the ovarian follicular law in terms of the number of oocytes that can be fertilized, protocols with a better ovarian stimulation are now considered, reducing risk of ovarian hyperstimulation syndrome, multiple pregnancies and emotional and psychological burdens on the patients. Long-acting FSH preps. are also under clinical study. Knowledge of the stereochem. three-dimensional structure of FSH and its receptor will allow the study of new non-peptide orally administered GnRH. that fit the FSH receptors.

L11 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
2005:1119466 Document No. 143:716 Small molecule agonists and antagonists for the LH and FSH receptors.
Chen, Tao (Pharmacopeia Drug Discovery, Inc., Princeton, NJ, 08543-5350, USA). Expert Opinion on Therapeutic Patents, 15(10), 1359-1364 (English) 2005. CODEN: EOTPEM. ISSN: 1354-3776. Publisher: Ashley Publications Ltd..
AB A review. Luteinizing hormone (LH) and FSH play a critical role in human reproduction. LH and FSH are secreted from the pituitary and act on their resp. G-protein-coupled receptors (GPCRs). LER and FSHR, in the gonads to either promote follicular growth and differentiation in women or LH stimulate the proper progression of spermatogenesis in men. LH and FSH are currently used in the clinic for the treatment of infertility. Small mol. agonists of LER and FSHR have the potential to become oral therapeutics for infertility treatment, whereas small mol. antagonists of LER and FSHR may find utility in oral contraception. Advances in cell. biol., high-throughput screening (HTS) and combinatorial chemical have made significant contributions to the recent discovery of a variety of small mol. LER and FSHR agonists and antagonists, some of which have shown highly promising efficacy in animal models of fertility control.

L11 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
2005:343830 Document No. 142:411120 Overriding follicle selection in controlled ovarian stimulation protocols: quality vs. quantity.
Stanford, Richard L.; Schlatt, Stefan. Mary S. Easton Division of Reproductive Science, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, 97006, USA). Reproductive Biology and Endocrinology, 3, No pp. Given (English) 2005. CODEN: RBEAOP. ISSN: 1477-7827. URL: http://www.rbej.com/content/pdf/1477-7827-3-13.pdf Publisher: BioMed Central Ltd..
AB A review. Selection of the species-specific number of follicles that will develop and ovulate during the ovarian cycle can be overridden by increasing the levels of pituitary gonadotropin hormones, FSH and LH. During controlled ovarian stimulation (COS) in nonhuman primates for assisted reproductive technol., ART) protocols, the method of choice (not the only method) has been the administration of exogenous gonadotropins, either of r. macaque or primate origin. Due to species-specificity of the primate LH (but not FSH) receptor, COS with exogenous (e.g., rhesus) hormones can be attributed to their FSH activity. Elevated levels of FSH alone will promote large ovarian follicles containing oocytes capable of fertilization in vitro (IVF). However, there is evidence that LH, probably in lesser amts., increases the rate of follicular development, reduces heterogeneity of the ovarian follicle pool, and improves the viability and rate of pre-implantation development of IVF-produced embryos. Since an endogenous LH surge typically does not occur during COS cycles (especially when a GnRH antagonist is added), a large dose of an LH-like hormone (i.e., hCG) may be given to replicate normal and produce fertilizable oocytes. Alternate approaches using a pure or LH low FSH), or GnRH agonist to induce an endogenous LH surge, have received lesser attention. Current protocols will routinely yield dozens of large follicles with fertilizable oocytes. However, limitations in some ovary-responding animals, heterogeneity of follicle/ lamb personality oocytes, and subsequent short luteal phases (limiting embryo transfer in COS cycles). However, the most serious limitation to further improvements and expanded use of COS protocols for ART is the lack of availability of nonhuman primate gonadotropins. Human, and even more so, nonprimate gonadotropins are antigenic in monkeys, which limits the number of COS cycles to as few as 1 (human) or 3 (recombinant hCG) protocols in macaques. Production and access to sufficient supplies of nonhuman primate FSH, LH, and CG would overcome this major hurdle.

L11 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
2003:215479 Document No. 139:11830 Development of hormonally based male contraceptives - a perspective. Nozawa, S. S. (Primate Research Laboratory, Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, 560 012, India). PINSA-B: Proceedings of the Indian National Science Academy, Part B: Biological Sciences, 68(1), 115-131 (English) 2002. CODEN: PNSBB2. Publisher: Indian National Science Academy.
AB A review. Hormonally based contraceptives in the male primarily act by interfering with the finely tuned testicular spermatogenic process. Development in this area has been dependent on our acquiring a complete knowledge on how the two pituitary hormones - FSH and LH regulate this complex event in the primate. Understanding the regulation of spermatogenesis in the primate including man has clearly underscored the importance of both gonadotropins - FSH and LH in this process. Testosterone (T) whose synthesis in the Leydig cell is regulated by LH has the important function of controlling meiosis, the step regulating the final phase of haploid sperm formation. Both up stream (spermatocytogenesis) and down stream (spermiogenic) events in spermatogenesis seem to be under the tight control of FSH. Thus while blockade of LH results in oligospermia accompanied by loss of libido due to significant inhibition in T production, the block of FSH function results in oligospermia which is accompanied by production of sperms incapable of achieving fertilization. The first part of this review highlights the extensive investigations carried out using the monkey as the human surrogate model to establish the above conclusions. While specific blockade of FSH was achieved by using GnRH or its receptor protein and GnRH or its GnRH antagonist or a recombinant FSH receptor protein fragment as an immunogen, blockade of both FSH and LH secretion/function could be achieved by interfering with hypothalamic-pituitary function using GnRH agonists/ antagonists or a combination of brain peptides (NPY) and tripeptides (TRH). The second part of this review describes the trials undertaken using primarily the monkey as the model to test the contraceptive efficacy of some of these procedures. The results of limited trials carried out in volunteer men using both FSH vaccine and GnRH plus a combination drug therapy has also been described. The advantages of pursuing some of the leads obtained in the above studies in the development of a viable, safe and reversible contraceptive for the male has been highlighted.

L11 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
2002:715349 Ovarian follicle development: the role of oocyte GDF-9 and GDF-9B/BMP-15. Hayashi, A. S. O.; Yan, C.-H. (Division of Reproductive Biology, Department of Gynecology and Obstetrics, Stanford University School of Medicine, Stanford, CA, 94305-5317, USA). Reproductive Medicine in the Twenty-First Century, Proceedings of the World Congress on Fertility and Sterility, 17th, Melbourne, Australia, 2001, Meeting Date 2001, 231-236. Editor(s): Healy, David L. Parthenon Publishing Group Inc.: Pearl River, N. Y. ISBN: 1-84214-036-1 (English) 2002. CODEN: 69WCAM.
AB A review discusses the role of GDF-9 and GDF-9B/BMP-15 in the development of ovarian follicles. It describes the oocyte control of early follicle development; addnl. role of GDF-9 during cyclic follicle recruitment; recombinant GDF-9 for ovulation induction and the design of GDF-9 antagonists as potential follicle preservation pills; GDF-9/GDF-9B pathway in infertility and fecundity; and the exclusion of inhibin-α and FSH receptor genes in human trimming genes.

L11 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
1999:317764 Document No. 131:11459 Role of FSH in male gonadal function.
Simoni, M.; Weinbauer, G. F.; Gromoll, J.; Nieschlag, E. (Institute of Reproductive Medicine of the University, Munster, D-48129, Germany). Annales d'Endocrinologie, 60(2), 103-106 (English) 1999. CODEN: ANDOAE. ISSN: 0003-4266. Publisher: Masson Editeur.
AB A review, with 23 refs. The production of male gametes depends on the concerted action of the two gonadotropins FSH and LH on the testis. The action of LH is mediated through the production of testosterone by the Leydig cells. Since male germ cells possess neither FSH nor androgen receptors, the action of FSH and testosterone occurs through the Sertoli cells. Although the precise function of these two hormones remains elusive, the existing evidence support that both FSH and testosterone are able to stimulate all phases of spermatogenesis. In the male FSH is required for the determination of Sertoli cell number, and for induction and maintenance of normal sperm production. The crucial role of FSH in male gonadal function has been clearly illustrated by the discovery of a patient with an activating mutation of the FSH receptor. This patient had been hypogonadotropic because of a pituitary tumor and, under testosterone substitution was unexceptionally fertile in spite of undetectable serum gonadotropin levels and had fathered three children. In this patient we would demonstrate a heterozygous activating mutation of the FSH receptor which resulted in cAMP production independent of FSH stimulation. This finding represents the first description of an activating mutation of the FSH receptor and demonstrates that FSH alone maintains spermatogenesis in man. On the other hand, the effects of the loss of FSH action are unclear. Among five men with a homozygous inactivating mutation of the FSH receptor only one was infertile and spermatogenesis was variably affected in the others. However, serum inhibin B values in these men were not completely suppressed and serum FSH levels were only moderately elevated, indicating the possibility that FSH receptor function was not completely abolished by the mutation. Elimination of FSH action is a prerequisite to suppress completely spermatogenesis for contraceptive purposes, while administration of both LH and FSH is necessary to induce sperm production in patients with hypogonadotropic hypogonadism. Rapid inactivation of male monkeys against FSH markedly reduced germ cell proliferation and even induced infertility. At the cellular level, FSH stimulates the cAMP-dependent activation of protein kinase A in Sertoli cells, but the mol. mechanism of FSH action is poorly understood. In the primate, the gonadotropin withdrawal achieved by administration of a GnRH antagonist leads to a premature arrest of germ cell proliferation, probably due to inhibition of the mitotic division of A-pale spermatogonia. Therefore, FSH might be the prime inducer of spermatogonial proliferation, while the successive maturation process could proceed independently of FSH. In summary, clin. and experi. evidence support the concept of an irreplaceable role of FSH in the primate. Only the combination of FSH and testosterone, however, supports a qual. and quant. fully normal spermatogenesis.

L12 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

10540336.trn

=> dhis
DHIS IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d his

(FILE 'HOME' ENTERED AT 16:51:11 ON 03 JUL 2007)

FILE 'REGISTRY' ENTERED AT 16:51:33 ON 03 JUL 2007
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 STRUCTURE UPLOADED
L4 1 S L3
L5 237 S L3 FULL

FILE 'CAPLUS' ENTERED AT 16:55:47 ON 03 JUL 2007
L6 5 S L5

FILE 'STNGUIDE' ENTERED AT 16:56:56 ON 03 JUL 2007

FILE 'REGISTRY' ENTERED AT 17:15:40 ON 03 JUL 2007
L7 ANALYZE L5 237 RN : 1 TERM
L8 ANALYZE L5 1-237 RN : 237 TERMS

FILE 'CAPLUS' ENTERED AT 17:19:01 ON 03 JUL 2007
L9 1529 S FSH RECEPTOR
L10 201 S L9 AND REVIEW/DT
L11 1 S L10 AND 1-0/CC
L12 6 S L10 AND ANTAGONIST

=> s l10 and SAR
11305 SAR
4011 SARS
15017 SAR
(SAR OR SARS)
L13 0 L10 AND SAR

=> s l9 and SAR
11305 SAR
4011 SARS
15017 SAR
(SAR OR SARS)
L14 8 L9 AND SAR

=> d scan

10540336.trn

L14 8 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
TI Discovery of potent biaryl diketopiperazine FSH receptor agonists: Rapid lead optimization through parallel synthesis

NOW MOST HORS ANSWERS DO YOU WISH TO SCAN? (1)1:1

L14 8 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
RE
1-3 (Pharmacology)
Section cross-reference(s): 28
IT 3-Alkylated thiazolidinones as follicle-stimulating hormone (FSH) receptor agonists
thiazolidinone group FSH receptor agonist SAR
IT Human
Structure-activity relationship
(3-alkylated thiazolidinones as FSH receptor agonists)
IT FSH receptors
RL: BPR (Biological study, unclassified); BSU (Biological study)
(3-alkylated thiazolidinones as FSH receptor agonists)
IT 9002-68-0, FSH
RL: BSU (Biological study, unclassified); BSU (Biological study)
(3-alkylated thiazolidinones as FSH receptor agonists)
IT 796861-70-2P 796861-71-3P
RL: PAC (Pharmacological activity); SCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(3-alkylated thiazolidinones as FSH receptor agonists)
IT 796861-72-4P 796861-73-5P 796861-74-6P 796861-75-7P 796861-76-8P 796861-77-9P 796861-78-0P 796861-79-1P 796861-80-4P 796861-81-5P 796861-82-6P 796861-83-7P 796861-84-8P 796861-85-9P 796861-86-0P 796861-87-1P 796861-88-2P 796861-89-3P 796861-90-6P 796861-91-7P 796861-92-8P 796861-93-9P 796861-94-0P 796861-95-1P 796861-96-2P 796861-97-3P 796861-98-4P 796861-99-5P 796862-00-1P 796862-01-2P 796862-02-3P 796862-03-4P 796862-04-5P 796862-05-6P 796862-06-7P 796862-07-8P 796862-08-9P 796862-09-0P 796862-10-3P 796862-11-4P 796862-12-5P 796862-13-6P 796862-14-7P 796862-15-8P 796862-16-9P 796862-17-0P 796862-18-1P 796862-19-2P 796862-20-5P 796862-21-6P 796862-22-7P 796862-23-8P 796862-24-9P 796862-25-0P 796862-26-1P 796862-27-2P 796862-28-3P 796862-29-4P 796862-30-7P 796862-31-8P 796862-32-9P 796862-33-0P 796862-34-1P 796862-35-2P 796862-36-3P 796862-37-4P 796862-38-5P 796862-39-6P 796862-40-9P 796862-41-0P 796862-42-1P 796862-43-2P 796862-44-3P 796862-45-4P 796862-46-5P 796862-47-6P 796862-48-7P 796862-49-8P 796862-50-1P 796862-51-2P 796862-52-3P 796862-53-4P 796862-54-5P 796862-55-6P 796862-56-7P 796862-57-8P 796862-58-9P 796862-59-0P 796862-60-3P 796862-61-4P 796862-62-5P 796862-63-6P 796862-64-7P 796862-65-8P 796862-66-9P 796862-67-0P 796862-68-1P 796862-69-2P 796862-70-5P 796862-71-6P 796862-72-7P 796862-73-8P 796862-74-9P 796862-75-0P 796862-76-1P 796862-77-2P 796862-78-3P 796862-79-4P 796862-80-7P 796862-81-8P 796862-82-9P 796862-83-0P 796862-84-1P 796862-85-2P 796862-86-3P 796862-87-4P 796862-88-5P 796862-89-6P 796862-90-9P 796862-91-0P 796862-92-1P 796862-93-2P 796862-94-3P 796862-95-4P 796862-96-5P 796862-97-6P 796862-98-7P 796862-99-8P 796863-00-4P 796863-01-5P
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(3-alkylated thiazolidinones as FSH receptor agonists)
IT 50-23-7, Normegestrone acid 130-38-7 496-69-2 1121-52-0 6129-44-1, Methyl hydroxylamine hydrochloride 4179-19-7, 4-Acetylacetophenone oxime 5810-18-9, Methyl 3-aminothiophene-2-carboxylate 7683-66-2, 4-Nitrophenyl chloroformate 10479-99-8 22978-25-2 84436-99-2 89971-78-1 179376-83-7, (1,1'-Biphenyl)-3-methanamine 202197-79-6 796869-69-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(3-alkylated thiazolidinones as FSH receptor agonists)
IT 186579-67-6P 796871-17-9P 796901-69-9P 796901-72-2P 796901-75-5P 796901-79-1P 796901-83-5P 796901-87-9P 796901-91-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(3-alkylated thiazolidinones as FSH receptor agonists)

NOW MOST HORS ANSWERS DO YOU WISH TO SCAN? (1)1:1

L14 8 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L14 8 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
TI Proline and piperidine acid-based agonists of the follicle-stimulating hormone receptor

NOW MOST HORS ANSWERS DO YOU WISH TO SCAN? (1)1:1






```
=> d his

     (FILE 'HOME' ENTERED AT 16:51:11 ON 03 JUL 2007)

     FILE 'REGISTRY' ENTERED AT 16:51:33 ON 03 JUL 2007
L1                STRUCTURE UPLOADED
L2              1 S L1
L3                STRUCTURE UPLOADED
L4              1 S L3
L5            237 S L3 FULL

     FILE 'CAPLUS' ENTERED AT 16:55:47 ON 03 JUL 2007
L6              5 S L5

     FILE 'STNGUIDE' ENTERED AT 16:56:56 ON 03 JUL 2007

     FILE 'REGISTRY' ENTERED AT 17:15:40 ON 03 JUL 2007
L7            ANALYZE L5 237 RN :         1 TERM
L8            ANALYZE L5 1-237 RN :       237 TERMS

     FILE 'CAPLUS' ENTERED AT 17:19:01 ON 03 JUL 2007
L9           1529 S FSH RECEPTOR
L10           201 S L9 AND REVIEW/DT
L11             1 S L10 AND 1-0/CC
L12             6 S L10 AND ANTAGONIST
L13             0 S L10 AND SAR
L14             8 S L9 AND SAR

=> d cbob abs hitstr
'CBOB' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
```



```
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):cbib abs
```




10540336.trn

=> d cbib abs 1-8

10540336.trn

L11 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
2006:661902 Structural exploration of a novel class of tricyclic benzodiazepine follicle-stimulating hormone receptor (FSH-R) antagonists: Part II. McClerman, Gareth D.; Felli, Rosanne M.; Spagliate, Emanuela A.; Santilli, Arthur A.; Coghlan, Richard B.; Trybulski, Eugene J.; Andrew, Patrick M.; Chen, Gi-Chung; Chi, Junia; Ostrowski, Tracy L.; Furst, Maria

Claudia; Shen, Emily S. (Chemical and Screening Sciences, Wyeth Research, Princeton, NJ, 08543, USA). Abstracts of Papers, 232nd ACS National Meeting, San Francisco, CA, United States, Sept. 10-14, 2006, MEDI-449. American Chemical Society: Washington, D. C. (English) 2006. CODEN: 69YIBB.

AB FSH (FSH) plays a crucial role in the regulation of female reproduction by

stimulating ovarian functions. Reports from clin. studies have described mutations in either FSH or its receptor that lead to a decrease in fertility or infertility. The development of specific antagonists of the FSH-receptor (FSH-R), therefore, would provide a novel strategy for non-steroidal hormonal contraception. We have succeeded in identifying a novel class of pyrrolobenzodiazepines, low mol. weight non-peptidic selective antagonists of the FSH-R, which inhibit FSH-R-dependent reporter gene activation and FSH-stimulated cAMP accumulation. The pyrrolobenzodiazepine lead (1) was conveniently divided

into three areas of investigations: the 3-aminomethyl headpiece, the tricyclic heterocyclic core and the biphenyl tailpiece. This poster will illustrate the extensive SAR exploration of the biphenyl region of the mol. leading to the identification of compds. that inhibited FSH-R-dependent reporter gene activation with low nanomolar potency and high efficacy.

L11 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
2006:179916 Document No. 144:164963 3-Alkylated thiazolidinones as follicle-stimulating hormone (FSH) receptor agonists. Trybul, Joey; Potter, James; Rao, Vaalingi; Bogarty, Joshua M.; Li, Chi, Junia; Furst, M. Claudia; Chen, Gi-Chung; Shen, Emily S. (Chemical and Screening Sciences, Wyeth Research, Collegeville, PA, 19426, USA). Bioorganic & Medicinal Chemistry Letters, 16(6), 1729-1741 (English) 2006. CODEN: BMCLE8, ISSN: 0960-894X. OTHER SOURCES: CASREACT 144:164963. Publisher: Elsevier B.V.,

GI

I

AB We prepared analogs of potent thiazolidinone-based FSH agonist 1. These compds. were evaluated in a Chinese hamster ovary (CHO) cell line that expressed recombinant human FSH receptor (FSHR) and a luciferase reporter gene regulated by a cAMP response element (CRE). Selected compds. were also tested on a CHO-cell line that over expressed the FSHR for the ability to induce cAMP production. When the 3-alkyl substituent was a Me group, similar FSH activity (i.e., EC50 = 61 nM, 100

efficacy relative to hFSH) to the analogous 3-hydrogen series compound was

observed; thus, proving that a small 3-alkyl substituent was well tolerated.

New series, in which the potentially hydrolytically labile secondary amide

function (-CONH-) was modified to other moieties (e.g., -CH2NH-, -CH2O-, and -CH2OCONH-), were also prepared and evaluated. These compounds also displayed good potency in the CRE-luciferase assay.

L11 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
2006:141170 Small molecule ligands of the follicle stimulating hormone receptor. Covel, Jonathan A.; Kaboth, Eric; Ongondi, Ronai Nwafiona, Peiwu; Ibarra, Joanna; Pulley, Michelle; Santoro, Vincent J.; Monahan, Paul; Gobb, Robert E.; Wilson, Carolyn; Lehmann-Grunkemm, Karin; Chang, Steve; Collins, Lara; Bo, Rongmei; Le, Thuy; Leonard, James; Liu, Chen; Sherwood, Gary; Tan, Lawrence; Walton, Tim (Lab, Arena Pharmaceuticals, San Diego, CA, 92121, USA). Abstracts of Papers, 231st ACS National Meeting, Atlanta, GA, United States, March 25-30, 2006, MEDI-117. American Chemical Society: Washington, D. C. (English) 2006. CODEN: 69YIBB.

AB Infertility is a worldwide problem afflicting millions. It can arise from

low levels of FSH (FSH), a pituitary gonadotropin which acts through a G-coupled GPCR. FSH receptors are found in the membrane of ovarian granulosa cells and are essential for folliculogenesis. FSH itself can be obtained from urine or produced from recombinant DNA techn. However, treatment with FSH is costly and inconvenient. To overcome these issues, we initiated a program to identify small mol. FSH modulators for the treatment of infertility. SAR development began around a lead structure containing a thiazole-piperidine core which was discovered from a proprietary, Constitutively Activated Receptor Technol. (CART) assay. The synthesis and biol. activity of several analogs from this effort will be described.

L11 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
2001:90931 Document No. 134:159414 First QSAR report on FSH receptor antagonistic activity: Quantitative investigations on physico-chemical and structural features among 4-amino-4-phenylpiperidine derivatives. Manivannan, L.; Prasanna, S. (School of Pharmacy, Devi Ahilya Vishwavidyalaya, Indore, 452017, India). Bioorganic & Medicinal Chemistry Letters, 11(3), 349-353 (English) 2001. CODEN: BMCLE8, ISSN: 0960-894X. Publisher: Elsevier B.V.,

AB A quant. attempt has been made to correlate the structure-activity relationship (SAR) among the recently reported 4-amino-4-phenylpiperidine derivs. as antagonists for the gonadotropin-coupled human FSH receptor. The compds. used for the present study have been reported to show high antagonistic efficacy in vitro using a 125I-hFSH(Liu) assay. Our QSAR investigations revealed a hypersaponic type of interactions between these ligands and the FSH receptor, hence confirming the presence of a lipophilic pocket at the active site of the target structure. The pos. coefficient of C log P variable in our derived QSAR model supports that

same

hydrophobic ligands are crucial for their FSH gonadotropic antagonistic efficacy. In employing the pharmacophoric requirement among these compounds, the authors found an amino linkage as conducive to their FSH receptor antagonistic activity. A 3D, 4-substituted 4-PA ring of the pharmacophore is less preferable for their FSH receptor antagonistic activity. The results discussed herein would be useful in understanding the nature of interactions of these newly identified ligands at FSH receptor antagonists and in designing more potent ligands based on this novel 4-amino-1-phenylpiperidine scaffold.

L11 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
2004:617894 Discovery of potent biaryl diketopiperazine FSH receptor agonists: Rapid lead optimization through parallel synthesis. Sun, Tsai Dung; Goldberg Fitzpatrick, Paula Gong, Feng; Su, Hao-Hsi; Jibilian, Charles H.; Holtgen, Steven G.; Lin, Haiyan; Goldwald, Edward; Salama, Mark F.; Salamonsen, Kenneth J.; Xie, Suzi Adang, Abbas E. P.; Von Strelow, Nicole K.; Webb, Maria L. (Pharmacopeia, Inc, Princeton, NJ, 08543-2190, USA). Abstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, United States, August 22-26, 2004, MEDI-017. American Chemical Society: Washington, D. C. (English) 2004. CODEN: 69YIBB.

AB FSH (FSH), a 35 kDa heterodimeric glycoprotein hormone, plays an important

role in human reproduction. FSH is responsible for ovarian follicle maturation

in women and for spermatogenesis in men. FSH signals through the FSH receptor (FSHR), a seven transmembrane G protein-coupled receptor (GPCR) expressed on granulosa cells in the female

and Sertoli cells in the male. In an effort to develop a small mol. FSHR agonist as a potential oral therapy for treating infertility and spermatogenesis disorders, ACLPS(TM) assisted combinatorial libraries were

screened using FSHR transfected cells to provide micromolar agonist hits. Based on these hits, three parallel libraries were designed and synthesized on solid phase, resulting in the discovery of potent nanomolar

biaryl diketopiperazine FSH receptor agonists. Details of the parallel synthesis and SAR will be presented.

L11 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
2004:616114 Document No. 141:79067 Small molecule biaryl FSH receptor agonists. Part 1. Lead discovery via extended combinatorial synthesis. Sun, Tsai Dung; Andrew M. P.; Bello, Roland G.; Dong, Yuzhong Fitzpatrick, Paula Gong, Feng; Su, Hao-Hsi; Holtgen, Steven G.; Lin, Haiyan; Goldwald, Edward; Mosmilovac, Brian G.; Salama, Mark F.; Salamonsen, Kenneth J.; Von Strelow, Nicole C. G.; Xie, Suzi; Webb, Maria L.

(Pharmacopeia, Inc., Princeton, NJ, 08543-2190, USA). Bioorganic & Medicinal Chemistry Letters, 14(17), 4713-4716 (English) 2004. CODEN: BMCLE8. ISSN: 0960-894X. Publisher: Elsevier Science B.V.,

GI



AB High-throughput screening of two million compds. in 17 distinct encoded combinatorial libraries using FSH receptor transfected cells provided small mol. agonists , based on which a focused combinatorial library with a total of 31,371 compds. was designed, synthesized, and screened to reveal 12 novel biaryl FSH receptor agonists such as 1 as well as a unique combinatorial SAR.

L11 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
2003:618154 Proline and piperidine urea-based agonists of the follicle-stimulating hormone receptor. Gonzalez, Andreas; Reddy, Achilles Liao, Yihan; Nagar, Sharad; Harvey, Robert; Velvel, Velchuri; Konduklia, Sreeram; Rosenthal, Jung; Dunlop, David; Cheng, Shirley; Liu,

Jane; McKenna, Sean; Jiang, Xialiang; Evans, David; Tepper, Mark; El Tayar, Nabil (German Reproductive Biology Institute, Rostock, MB, 02370, USA). Abstracts of Papers, 226th ACS National Meeting, New York, NY, United States, September 7-11, 2003, MEDI-345. American Chemical society:

Washington, D. C. (English) 2003. CODEN: 69IYYB.

AB FSH (FSH) is a native glycoprotein hormone that is necessary for follicle growth. This action is mediated via a specific G protein-coupled receptor, the FSH receptor (FSHR), present in the membrane of granulosa cells within the follicles of the ovary. Decreased levels of FSH result in reduced fertility or infertility. In an effort to

develop a small-mol. FSH receptor agonist, a series of substituted prolines was found to mimic the action of FSH in cells expressing the FSHR. An SAR around this series was developed and is described herein. A piperidine homolog was found to have a tenfold

increased potency than its proline congener. This compound induced cAMP production in CHO cells expressing the FSH receptor, but not in parental cells, or in cells expressing the other two glycoprotein hormone receptors (LSH and TSHR). In addition, this compound similarly to FSH,

induced estradiol release from rat granulosa cells.

L11 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
2003:618706 Small Molecule FSH-mimetics. El Tayar, Nabil; Reddy, Achilles Liao, Yihan; Nagar, Sharad; Harvey, Robert; Konduk, Richard; Velvel, Velchuri Konduklia, Sreeram; Rosenthal, Jung; Dunlop, David; Cheng, Shirley; Liu, Jane; McKenna, Sean; Jiang, Xialiang; Evans, David; Tepper, Mark; Gonzalez, Andreas (Department of Medicinal Chemistry, German Reproductive Biology Institute, Rostock, MB, 02370, USA). Abstracts of Papers, 226th ACS National Meeting, Boston, MA, United States, August 29-31, 2003, MEDI-315. American Chemical Society: Washington, D. C. (English) 2003. CODEN: 69CJPX.

AB FSH (FSH) is a native glycoprotein hormone that is necessary for follicle growth. This action is mediated via a specific G protein coupled receptor, the FSH receptor (FSHR), present in the membranes of granulosa cells within follicles. An effort to discover a small orally bioavailable mol. that mimics the activity of FSH by activating the FSHR was initiated with the screening of com. and inhouse libraries. The positives identified in the screen led to a "hit-to-lead" effort around a proline-containing series. The prototype of this series, AJ700616, induced cAMP production in CHO cells expressing the human FSHR, but

not in parental cells or in cells expressing the human LHR. In addition AJ700616, similarly to FSH, induced estradiol release from rat granulosa cells, and also increased the proliferative activity of these cells. Studies leading to the identification of AJ700616 and SAR developed around the hit mol. will be discussed.

10540336.trn

=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 17:29:42 ON 03 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 29, 2007 (20070629/UP).

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.50	300.71
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-16.38

STN INTERNATIONAL LOGOFF AT 17:44:51 ON 03 JUL 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTADKO1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	3	MAR 16	CASREACT coverage extended
NEWS	4	MAR 20	MARPAT now updated daily
NEWS	5	MAR 22	LWPI reloaded
NEWS	6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	10	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS	11	APR 30	INPADOC replaced by INPADOCDB on STN

```
 NEWS 12   MAY 01   New CAS web site launched
 NEWS 13   MAY 08   CA/CAplus Indian patent publication number format defined
 NEWS 14   MAY 14   RDISCLOSURE on STN Easy enhanced with new search and display
                    fields
 NEWS 15   MAY 21   BIOSIS reloaded and enhanced with archival data
 NEWS 16   MAY 21   TOXCENTER enhanced with BIOSIS reload
 NEWS 17   MAY 21   CA/CAplus enhanced with additional kind codes for German
                    patents
 NEWS 18   MAY 22   CA/CAplus enhanced with IPC reclassification in Japanese
                    patents
 NEWS 19   JUN 27   CA/CAplus enhanced with pre-1967 CAS Registry Numbers
 NEWS 20   JUN 29   STN Viewer now available
 NEWS 21   JUN 29   STN Express, Version 8.2, now available
 NEWS 22   JUL 02   LEMBASE coverage updated
 NEWS 23   JUL 02   LMEDLINE coverage updated
 NEWS 24   JUL 02   SCISEARCH enhanced with complete author names
 NEWS 25   JUL 02   CHEMCATS accession numbers revised
 NEWS 26   JUL 02   CA/CAplus enhanced with utility model patents from China

 NEWS EXPRESS   29 JUNE 2007:  CURRENT WINDOWS VERSION IS V8.2,
                CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
                AND CURRENT DISCOVER FILE IS DATED 4 MAY 2007.

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:21:43 ON 05 JUL 2007

=> file reg
FILE 'REGISTRY' ENTERED AT 08:22:11 ON 05 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     4 JUL 2007  HIGHEST RN 941231-35-2
DICTIONARY FILE UPDATES:    4 JUL 2007  HIGHEST RN 941231-35-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.
```



```
REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s 341938-66-7/rn
L1            1 341938-66-7/RN

=>
Connection closed by remote host

Connecting via Winsock to STN



Welcome to STN International!  Enter x:X

LOGINID:SSPTADKO1625

PASSWORD:
  * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 08:23:09 ON 05 JUL 2007
FILE 'REGISTRY' ENTERED AT 08:23:09 ON 05 JUL 2007
COPYRIGHT (C) 2007 American Chemical Society (ACS)
=> s 341938-66-7/rn
L2            1 341938-66-7/RN

=> d l2 full
'FULL' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual
fields or predefined formats.  The predefined substance formats
are:  (RN = CAS Registry Number)

REG     - RN
SAM     - Index Name, MF, and structure - no RN
FIDE    - All substance data, except sequence data
IDE     - FIDE, but only 50 names
SQIDE   - IDE, plus sequence data
SQIDE3  - Same as SQIDE, but 3-letter amino acid codes are used
SQD     - Protein sequence data, includes RN
SQD3    - Same as SQD, but 3-letter amino acid codes are used
SQN     - Protein sequence name information, includes RN

CALC    - Table of calculated properties
EPROP   - Table of experimental properties
PROP    - EPROP and CALC

Any CA File format may be combined with any substance format to
obtain CA references citing the substance.  The substance formats
must be cited first.  The CA File predefined formats are:
```



```
ABS   -- Abstract
APPS  -- Application and Priority Information
BIB   -- CA Accession Number, plus Bibliographic Data
CAN   -- CA Accession Number
CBIB  -- CA Accession Number, plus Bibliographic Data (compressed)
IND   -- Index Data
IPC   -- International Patent Classification
PATS  -- PI, SO
STD   -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when
it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented,
with text labels.

For additional information, please consult the following help
messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):fide
```

10540336.trn

=> s 717855-78-2/rn
L3 1 717855-78-2/RN

=> d l3 fide

10540336.trn

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 717855-78-2 REGISTRY

ED Entered STN: 29 Jul 2006

CN Benzamide, N-[(1-acetyl-3-[(3-aminoethoxy)-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-phenyl-6-quinolinyl)-2,5-dibromo- (9CI) (CA INDEX NAME)

MF C19 H21 Br2 N2 O3

CI COM

SR CA

Ring System Data

Elemental(Elemental) Analysis	Sequence	Size of Ring System	Formula	Ring	RID	Occurrences Count
	ES	S1	S2	RID		
C6	C6	16	C6	66,230.19	11	
C10-C6	C9-C6	16-6	C6H9	391,79.39	11	



Predicted Properties (PROP)

PROPERTY (CODE)	VALUE	CONDITION	NOTE
Biocons. Factor (BCF)	124.71	pH 2 25 deg C	(11)
Biocons. Factor (BCF)	129.68	pH 2 25 deg C	(11)
Biocons. Factor (BCF)	129.02	pH 2 25 deg C	(11)
Biocons. Factor (BCF)	130.23	pH 4 25 deg C	(11)
Biocons. Factor (BCF)	141.70	pH 5 25 deg C	(11)
Biocons. Factor (BCF)	1156.45	pH 6 25 deg C	(11)
Biocons. Factor (BCF)	11260.36	pH 7 25 deg C	(11)
Biocons. Factor (BCF)	11967.50	pH 8 25 deg C	(11)

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN (Continued)

Molar Solubility (810.MOL)	(0.0000015 mol/L	(pH 9 25 deg C (11)
Molar Solubility (810.MOL)	(0.00000047 mol/L	(pH 9 25 deg C (11)
Molar Solubility (810.MOL)	(0.00000030 mol/L	(pH 10 25 deg C (11)
Molar Solubility (810.MOL)	(0.0000015 mol/L	(Unbuffered Water (11
		(pH 7.96
		(10 deg C
Molar Volume (MVOL)	(415.8+/-1.0 cm**3/mol	(20 deg C (11)
		(760 Torr
Mole-molar Refrac (MR)	(629.20	(11)
PKA (PKA)	(11.19+/-0.60	(Most Acidic (11
		(25 deg C
PKA (PKB)	(8.45+/-0.10	(Most Basic (11
		(25 deg C
Polar Surface Area (PSA)	(89.66 A**2	(11)
Vapor Pressure (VP)	(2.57E-13 Torr	(10 deg C (11)

(11) Calculated using Advanced Chemistry Development (ACD/Labs) Software V8.19 (C) 1994-2007 ACD/Labs

See HELP PROPERTIES for information about property data sources in REGISTRY.

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN (Continued)

Biocons. Factor (BCF)	(29157.22	(pH 8 25 deg C (11)
Biocons. Factor (BCF)	(34250.63	(pH 10 25 deg C (11)
Boiling Point (BP)	(697.7+/-55.0 deg C	(760 Torr (11)
Density (DEN)	(1.444+/-0.06 g/cm**3	(760 Torr (11)
Enthalpy of Vap. (ENVP)	(102.17+/-3.0 kJ/mol	(760 Torr (11)
Flash Point (FP)	(375.0+/-31.5 deg C	(11)
Freely Rotatable Bonds (FRB)	(7	(11)
H acceptor (HAC)	(5	(11)
H donor (HDN	(3	(11)
Hydrogen Bonds/Acceptors (HB)	(9	(11)
(HBA)		
Mor (EDC)	(43.44	(pH 2 25 deg C (11)
Ebc (EDC)	(50.89	(pH 2 25 deg C (11)
Ebc (EDC)	(49.93	(pH 2 25 deg C (11)
Ebc (EDC)	(53.19	(pH 4 25 deg C (11)
Ebc (EDC)	(73.45	(pH 5 25 deg C (11)
Ebc (EDC)	(275.79	(pH 6 25 deg C (11)
Ebc (EDC)	(2279.97	(pH 7 25 deg C (11)
Ebc (EDC)	(14715.01	(pH 8 25 deg C (11)
Ebc (EDC)	(89680.62	(pH 9 25 deg C (11)
Ebc (EDC)	(68722.64	(pH 10 25 deg C (11)
LogD (LogD)	(2.11	(pH 1 25 deg C (11)
LogD (LogD)	(1.98	(pH 2 25 deg C (11)
LogD (LogD)	(1.21	(pH 3 25 deg C (11)
LogD (LogD)	(3.32	(pH 4 25 deg C (11)
LogD (LogD)	(3.36	(pH 5 25 deg C (11)
LogD (LogD)	(3.94	(pH 6 25 deg C (11)
LogD (LogD)	(4.45	(pH 7 25 deg C (11)
LogD (LogD)	(4.72	(pH 8 25 deg C (11)
LogD (LogD)	(4.19	(pH 9 25 deg C (11)
LogD (LogD)	(4.29	(pH 10 25 deg C (11)
LogP (LogP)	(4.305+/-0.702	(15 deg C (11)
Mass Intrinsic Solubility (ISLB.MASS)	(0.00023 g/L	(25 deg C (11)
Mass Solubility (SLB.MASS)	(0.33 g/L	(pH 1 25 deg C (11)
Mass Solubility (SLB.MASS)	(0.29 g/L	(pH 2 25 deg C (11)
Mass Solubility (SLB.MASS)	(0.29 g/L	(pH 3 25 deg C (11)
Mass Solubility (SLB.MASS)	(0.29 g/L	(pH 4 25 deg C (11)
Mass Solubility (SLB.MASS)	(0.29 g/L	(pH 5 25 deg C (11)
Mass Solubility (SLB.MASS)	(0.053 g/L	(pH 6 25 deg C (11)
Mass Solubility (SLB.MASS)	(0.0063 g/L	(pH 7 25 deg C (11)
Mass Solubility (SLB.MASS)	(0.00069 g/L	(pH 8 25 deg C (11)
Mass Solubility (SLB.MASS)	(0.00038 g/L	(pH 9 25 deg C (11)
Mass Solubility (SLB.MASS)	(0.00054 g/L	(pH 10 25 deg C (11)
Mass Solubility (SLB.MASS)	(0.00054 g/L	(Unbuffered Water (11
		(pH 7.96
		(10 deg C
Molar Intrinsic Solubility (ISLB.MOL)	(0.00000036 mol/L	(25 deg C (11)
Molar Solubility (SLB.MOL)	(0.00052 mol/L	(pH 1 25 deg C (11)
Molar Solubility (SLB.MOL)	(0.00046 mol/L	(pH 2 25 deg C (11)
Molar Solubility (SLB.MOL)	(0.00046 mol/L	(pH 3 25 deg C (11)
Molar Solubility (SLB.MOL)	(0.00046 mol/L	(pH 4 25 deg C (11)
Molar Solubility (SLB.MOL)	(0.00012 mol/L	(pH 5 25 deg C (11)
Molar Solubility (SLB.MOL)	(0.000084 mol/L	(pH 6 25 deg C (11)
Molar Solubility (SLB.MOL)	(0.000010 mol/L	(pH 7 25 deg C (11)

10540336.trn

=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 08:27:23 ON 05 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 29, 2007 (20070629/UP).

=> d cost

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
CONNECT CHARGES	0.00	2.88
NETWORK CHARGES	0.06	0.54
DISPLAY CHARGES	0.00	7.18
FULL ESTIMATED COST	0.06	10.60

IN FILE 'STNGUIDE' AT 08:27:30 ON 05 JUL 2007

=>
=>
=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 09:06:16 ON 05 JUL 2007